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Introduction: Diagnosing influenza in the emergency department (ED) remains a challenge as 
physicians have no reliable tools to accurately and rapidly diagnose influenza; however, rapid 
diagnosis is crucial to begin antiviral therapy in patients with complications or at risk of 
complications from influenza.  Centers for Disease Control and Prevention (CDC) Guidelines 
recommend prompt antiviral treatment for patients who are hospitalized, at extremes of age (<5 
years old, >65 years old), or have a chronic disease or conditions putting them at increased risk of 
complications.   
 
Methods: First, we determined compliance with CDC antiviral guidelines via a retrospective 
evaluation of ED patients with confirmed influenza.  Then, we created a prospective cohort of ED 
patients who met CDC criteria for recommended antiviral treatment who were evaluated for 
influenza by 3 means: clinical diagnosis, a new molecular-based rapid test, and a Polymerase 
Chain Reaction (PCR) test.  Comparing the clinical diagnosis and rapid influenza test to the 
standard PCR assay allowed for a performance evaluation of both clinician diagnosis, and the 
new molecular-based rapid test.  Finally, a cost-effectiveness analysis was performed to compare 
influenza testing and treatment strategies. 
 
Results: ED providers have poor compliance with CDC guidelines regarding antiviral treatment 
with only 41% of patients recommended to receive antiviral treatment being treated in the ED.  
Provider diagnosis for influenza has a poor sensitivity of 36%, especially compared to the 
molecular-based rapid influenza test which has 95% sensitivity in the same population.  Finally, 
the most cost-effective testing and treatment strategy depends on influenza prevalence with rapid 
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testing as the most cost-effective treatment at low influenza prevalence, and treating all patients 
without testing as the most cost-effective strategy at high prevalence. 
 
Conclusions: The challenges of making a clinical diagnosis of influenza in the ED, and current 
lack of a rapid sensitive influenza test, likely contribute to poor compliance with current CDC 
guidelines regarding antiviral administration.  Integrating a new highly sensitive molecular-based 
rapid influenza test into ED clinical care, could improve compliance with CDC guidelines and is 
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Each year, influenza affects approximately 5-20% of the United States population causing over 
200,000 hospitalizations and 3,000 – 49,000 deaths [1-3].  This substantial societal impact will 
further increase during severe epidemics with increased prevalence or virulence causing 
additional morbidity and mortality.  As a key point of entry to the health care system, emergency 
departments (ED) are responsible for the initial management and treatment of a substantial 
proportion of these influenza patients, thus directly impacting overall public health.  Fortunately, 
the past 15 years has brought both new antiviral medications and increasing evidence of their 
effectiveness in specific populations.  
 
INFLUENZA ANTIVIRAL TREATMENT 
Though of questionable benefit in healthy individuals, antiviral treatment for patients at increased 
risk or with existing complications is recommended by the Centers for Disease Control and 
Prevention (CDC), World Health Organization (WHO), and the Infectious Disease Society of 
America (IDSA) [4-6].  Recent CDC guidelines recommend antiviral treatment specifically for 
patients with a severe or complicated course, hospitalization, or at high risk of influenza 
complications – including those younger than 5 years old, older than 65 years old, residing in a 
chronic-care facility, or with chronic medical conditions, immunosuppression, pregnancy, or 
morbid obesity [4].  
 
Research involving antiviral use and clinical outcomes in these high-risk patients is extremely 
complex, limiting the availability of definitive randomized controlled studies.  The majority of 
patients included in the clinical trials originally performed to demonstrate the effectiveness of 
antivirals did not have existing influenza-related complications or other characteristics placing 
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them at increased risk of complications [7,8].  These studies did show a decrease in the incidence 
of pneumonia and infectious complications in patients taking influenza antivirals, but were not 
properly powered to detect a potential impact on hospital admission or mortality due to the low 
event rate of these serious outcomes.  One of the few randomized controlled trials for high risk 
patients was performed in children with asthma, and showed improved pulmonary function and 
fewer asthma exacerbations in children receiving antiviral medication [9].   
 
In spite of the lack of randomized trials, a growing body of observational studies supports 
antiviral treatment in populations with or at increased risk of influenza related complications.  
The greatest evidence to date is in admitted patients, where numerous observational studies show 
a reduction in mortality, hospitalization, intensive care unit (ICU) admission and hospital length 
of stay associated with oseltamivir treatment [10-13].  Additional studies in specific at risk 
populations demonstrate reduction in hospitalization and death in patients with diabetes, 
pregnancy, and nursing home residence [14-17].  In their recommendations, both the WHO and 
CDC emphasize administering antiviral medications to patients with suspected, but not yet 
confirmed infections, as the time from symptom onset to antiviral treatment impacts patient 
outcomes [18-21]. 
 
Antiviral medications are currently recommended to be given within 48 hours of symptom onset, 
and appear to have increased effectiveness when given closer to the time of symptom onset.  
Several studies have demonstrated that further reducing the time between symptom onset and 
antiviral administration to 30 or even 24 hours, increases the beneficial effect of antivirals [18-
21].  Although 48 hours from symptom onset is a common cut off in deciding to administer 
antivirals, this boundary is blurred by evidence that some populations, such as patients admitted 
to the hospital, may continue to receive benefit from antivirals when initiated beyond the 48 hour 
cut-off [11-13].  Despite the evidence that shortening the time between symptom onset and 
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antiviral administration results in improved outcomes, the practical ability to diagnose and treat 
influenza within this 48 hour time frame is difficult due to the lack of reliable rapid diagnostic 
tools. 
 
RAPID DIAGNOSIS OF INFLUENZA 
The current lack of reliable rapid influenza tests make diagnosis and timely treatment of influenza 
challenging, especially in fast-paced treatment settings such as the ED. There are currently no 
reliable methods to diagnose influenza in the timeframe of a typical ED visit, leaving emergency 
physicians to make diagnostic and treatment decisions with limited, insufficient information.  The 
previous gold standard influenza test, viral culture, requires 3-10 days to perform, and is quickly 
being replaced by the more sensitive real-time polymerase chain reaction (rt-PCR), which 
typically requires several hours to result and is usually performed as batch testing, further 
lengthening time to result. Some laboratories utilize direct immunofluorescence assays (DFA), 
with moderate sensitivity of 50-80% for influenza and results in 30-60 minutes [22].  In an 
attempt to fill the need for rapid diagnosis, several rapid influenza tests have been developed; 
however, these antigen-based tests have sensitivities ranging from 10-70%, and current CDC 
guidelines require additional testing in the setting of a negative rapid influenza test due to their 
poor sensitivity [23].   
 
Given the lack of reliable testing options which yield rapid results, emergency physicians often 
diagnose influenza based on symptoms.  Many studies have attempted to validate the use of 
clinical symptoms to diagnose influenza overall showing poor sensitivity and specificity.  One of 
the largest studies showed that a combination of fever and cough had a sensitivity 64% and 
specificity 67% [24].  Two subsequent meta-analyses confirmed that there are no symptoms or 
combination of symptoms which has adequate sensitivity to make informed clinical decisions 
regarding influenza treatment [25,26].  
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Cepheid’s Xpert flu test is a new molecular-based rapid influenza test which yields a result in 80 
minutes and has recently obtained Food and Drug Administration (FDA) approval for influenza 
testing.  Previous validation studies performed in comparison to Luminex rt-PCR report a 
sensitivity of 91.2% and specificity of 99.4% giving an overall positive predictive value of 99.2% 
and negative predictive value of 93.1% [27].  Although promising, and with superior results 
compared to current antigen-based rapid influenza diagnostic tests, Xpert Flu has not been 
clinically validated or integrated into clinical practice. 
 
CURRENT ED PRACTICE 
Given the current difficulties of rapid diagnosis of influenza, and the evidence of improved 
antiviral efficacy when administered closer to the time of symptom onset, the CDC currently 
recommends that physicians treat patients who have an increased risk of influenza-related 
complications and suspected influenza with antivirals without waiting for confirmatory testing 
[4,28].  Despite the building evidence, and recommendations from expert organizations, patients 
remain under-treated with antivirals, and there continues to be a gap between recommendations 
and current clinical practice [29].  A survey of 1,055 ED clinicians during the 2006 -2007 
influenza season revealed that only 56% of ED clinicians prescribed antiviral medications for 
some of their influenza patients that year [30].  Though this survey occurred before the current, 
more expansive CDC influenza treatment guidelines, the low number of prescribing ED clinicians 
is shocking considering the volume of influenza-like illness (ILI) and influenza patients treated in 
the ED, and the prevalence of high-risk criteria such as diabetes, cardiac disease, age greater than 
65, and obesity in a typical ED population.  This trend of under-treatment continues through the 
2009 influenza season, where a retrospective evaluation of ED visits showed that only 50% of 
high-risk patients with a clinical diagnosis of influenza received antiviral treatment [31].  Despite 
the increased emphasis on rapid antibiotic administration in pneumonia and sepsis, antiviral use 
in the ED remains under-utilized.  In an observational study of 327 patients admitted with 
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influenza, 89% received antibacterial therapy, whereas only 32% were prescribed antiviral 
medications despite the fact that the majority (59%) presented to the ED within 48 hours of onset 
of illness [11].  In fact, only 50% of these patients received influenza testing from the ED.  The 
reticence of ED clinicians to prescribe antivirals has multiple possible explanations including 
difficulty confirming the diagnosis of influenza, as evidenced by numerous studies which have 
demonstrated the logical connection between increased influenza testing and increased antiviral 
use [30,32-34].  Other considerations contributing to the lack of influenza testing or treatment in 
the ED include economic concerns due to the high cost of oseltamivir treatment. 
 
COST-EFFECTIVENESS ANALYSIS 
Similar to the randomized controlled clinical effectiveness studies, the majority of the cost-
effectiveness analyses of influenza treatment have focused on healthy adults.  These studies often 
conclude that the most cost effective strategy is to treat all patients with antiviral medications, 
driven largely by a 1-2 day reduction in symptoms and decrease in lost work costs [35,36].  Cost-
effectiveness studies examining patients at increased risk of influenza complications are more 
varied with some recommending influenza testing as the most cost-efficient method [37,38], and 
others continuing to recommend to treat all without testing [39].  When considering influenza 
testing, these studies have considered the accurate but expensive rt-PCR testing, or the less-
expensive but inaccurate antigen-based rapid testing.  New molecular-based rapid tests, with a 




Despite growing evidence that influenza antivirals reduce morbidity and mortality in specific 
populations, and that antiviral medications are most effective when administered within 48 hours 
of symptom onset, ED physicians often do not prescribe them.  There are several contributing 
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factors to this gap in current medical practice, including the current challenges with reliable rapid 
diagnosis, as demonstrated in Figure 1Figure 1.  This work seeks to identify and quantify the 
current challenges of influenza diagnosis and treatment, and identify cost-effective solutions 
through the following four aims: 
 
Aim 1: Determine compliance with CDC antiviral administration guidelines amongst 
patients with a positive influenza test sent from the ED.  This aim will assess the current 
proportion of influenza patients either at risk of or with potential influenza related complications 
who receive antiviral treatment. 
 
Aim 2: To determine the current rate of influenza misdiagnosis in the ED.  Identifying the 
current rate of influenza misdiagnosis quantifies the current challenges of clinical influenza 
diagnosis. 
 
Aim 3: To evaluate the clinical sensitivity and specificity of a novel molecular-based rapid 
influenza test (Cepheid Xpert Flu).  This aim establishes the clinical validity of Cepheid Xpert 
Flu, and allows for comparison to other current diagnostic methods. 
 
Aim 4: To determine the cost-effectiveness of influenza testing and treatment strategies for 
adults who present to the ED with an acute respiratory illness and meet CDC criteria for 
influenza treatment.  Understanding the societal costs and benefits of these treatment strategies 
will help guide future clinical decision making and potential integration of new rapid influenza 
tests. 
 
Aim 1 quantifies the essential problem of low administration of antivirals by retrospectively 
evaluating the proportion of patients with confirmed influenza who are recommended to receive 
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antivirals according to current CDC guidelines that receive antiviral treatment in the ED.  
Additionally, it will explore potential factors such as severity of illness or hospital admission that 
may be associated with antiviral treatment.  This aim will be accomplished through a 
retrospective cohort of ED patients with confirmed influenza.  One contributor to the lack of 
antiviral administration in the ED is the challenge of rapid influenza diagnosis due to the time 
constraints of current testing and inaccuracy of clinical signs and symptoms.  Aim 2 quantifies 
the current problems with influenza misdiagnosis in the ED through a prospective study 
comparing ED provider clinical diagnosis to rt-PCR testing.  One potential solution to improve 
provider diagnosis is implementing a molecular-based rapid influenza test, such as Xpert Flu.  
Aim 3 demonstrates the clinical validity of Xpert Flu by assessing the sensitivity and specificity 
of Xpert Flu, compared to rt-PCR, in the same prospective population used to evaluate the 
provider clinical diagnosis.  This allows for direct comparison of the validity of these two 
potential diagnostic methods.  Finally, Aim 4 uses a cost utility analysis to identify the most cost 
effective approach to influenza management: rapid testing, clinical assessment, treat all, or treat 
none.  Combined, these four aims provide a comprehensive approach to quantify and address the 






























Aim 1: Compliance with Influenza Antiviral Recommendations 
 
INTRODUCTION 
Each year, influenza affects approximate 5-20% of the United States population causing over 
200,000 hospitalizations and 3,000 – 49,000 deaths [1-3].  As one of the primary points of entry 
to the health care system, EDs are responsible for initial management and treatment of a 
substantial proportion of these influenza patients [40].  Antiviral treatment has been demonstrated 
to improve clinical outcomes for patients at increased risk for, or with existing complications, and 
is thus recommended by the CDC, WHO and IDSA [4-6].  Recent CDC guidelines provide 
specific recommendation for antiviral treatment including patients with a severe or complicated 
course, those requiring hospitalization, or those at high risk of influenza complications – 
including those younger than 2 years, older than 65 years, residing in a chronic-care facility, or 
with chronic medical conditions, immunosuppression, pregnancy, or morbid obesity [4]. 
 
Despite growing evidence that antiviral medications reduce influenza-related morbidity and 
mortality, and the release and dissemination of recommendations from multiple expert 
organizations, there continues to be a substantial gap between recommendations and current 
clinical practice [29].  One recent study which prospectively tested 1,657 ED patients for 
influenza between 2009 and 2011 demonstrated that more than 80% of patients with confirmed 
influenza in the ED did not receive antiviral treatment [41].  However over half of the patients in 
that study did not meet CDC criteria for recommended antiviral treatment, and the study did not 
fully evaluate adherence with CDC antiviral recommendations.  Another single institution study 
evaluated ED adherence with CDC antiviral treatment recommendations and found that only 50% 
of patients with a final ED physician diagnosis of influenza, who met CDC criteria for treatment, 
actually received antiviral treatment [31].  However, the inclusion criteria used in this evaluation, 
a clinical diagnosis of influenza, has poor sensitivity for influenza [42].  Though previous 
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evaluations suggest that ED patients with influenza remain significantly undertreated, adherence 
to CDC guidelines amongst ED patients with confirmed influenza remains unknown. 
 
Given the challenges of diagnosing influenza in the ED, and the importance of appropriately 
treating patients with existing or at increased risk of influenza-related complications, we sought to 
determine adherence with CDC antiviral recommendations amongst a cohort of ED patients with 
laboratory confirmed influenza.  Understanding antiviral treatment patterns amongst this 
population could provide opportunities to improve ED care and potentially impact long term 





We performed an observational cohort study of ED patients with laboratory confirmed influenza 
at an urban, university-affiliated tertiary care center with an ED volume of over 60,000 annual 
patient visits.  This study was approved by the Johns Hopkins institutional review board with a 
waiver of consent. 
 
Study Population 
Adult subjects (18 years old or older) were included in the study if they had an ED visit between 
December 2008 and December 2012, and had a positive influenza test sent from the ED.  Subjects 
were excluded if they left the ED prior to completion of their ED work up and treatment, defined 







Patient records of all ED patients with laboratory confirmed influenza were screened in duplicate 
to ensure all inclusion criteria, and no exclusion criteria were met.  Two reviewers independently 
extracted data from the hospital’s electronic medical record, which included both ED and 
inpatient documentation.  We established the data points and data abstraction process prior to 
study initiation. Data were entered directly onto a standardized, closed entry, Microsoft Access 
(Microsoft Corporation, Redmond, Washington) database form.  Data elements recorded include: 
subject demographics, current symptoms, past medical history, current medication use, initial ED 
vital signs, laboratory and culture data, ED management, disposition from the ED, and final ED 
diagnoses.  Additionally, we collected information regarding the hospital course including 
influenza antiviral treatment while in the hospital. 
 
Measurements 
Using the abstracted information, subjects were categorized as either “recommended to receive 
antiviral treatment” or “not recommended to receive antiviral treatment” based on 2011 CDC 
guidelines [4].  Each subject was assigned to one of the 5 included influenza seasons (2008-2009, 
2009-2010, 2010-2011, 2011-2012, 2012-2013) based upon the date of ED presentation, with 
each influenza season spanning from May 15th to May 14th of the following year.  Duration of 
total symptoms was recorded and dichotomized as either 48 hours or less, or over 48 hours, based 
upon previous cut-offs for antiviral use in the literature [18].  Presence or absence of ILI was 
based upon the CDC criteria for ILI of a fever equal to or greater than 37.8 Celsius with either 
cough or sore throat [43].  Antibiotic and antiviral administration was recorded as either none, 
administered in the ED, or discharged with a prescription.  If a subject was either administered an 
antiviral in the ED, or discharged from the ED with an antiviral prescription, they were 
considered to have received ED antiviral treatment.  Similarly, if a subject was either 
administered an antibiotic in the ED or discharged from the ED with an antibiotic prescription, 
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they were considered to have received ED antibiotic treatment.  Time variables were documented 
according to the medical record date and time stamp for critical events, including time of arrival 
(initial registration), time of antiviral administration, time the first positive influenza test resulted, 
and time the subject left the ED.  If the time of the first positive influenza test result occurred 
prior to the time the subject left the ED, it was assumed that the influenza test result was available 
prior to disposition.  For each subject, the Pneumonia Severity Index (PSI) was calculated as 
described previously as a marker of illness severity [44,45].   
 
Data Analysis 
Data were analyzed using Stata Statistical Software: Release 11 (StataCorp LP, 2009. College 
Station, TX).  We used non-parametric statistics with results shown as medians and interquartile 
ranges (IQR) for continuous variables, and counts and percentages for dichotomous variables.  
Statistical comparisons were completed using chi-squared analysis.  For all tests, the level of 
significance was set to α = 0.05. 
 
Subjects were initially divided into two groups, those recommended to receive antiviral 
medication and those not recommended to receive antiviral medication.  The remainder of the 
analysis focused only on the group of subjects recommended to receive antiviral medication 
according to 2011 CDC guidelines, as this was the population of greatest interest.  Subjects 
recommended to receive antiviral treatment were further divided into those who received ED 
antiviral treatment and those who did not.  The primary outcome of this study is the proportion of 
subjects recommended to receive antiviral treatment who received ED antiviral treatment.  With a 
sample size of 282 subjects recommended to receive antiviral treatment, and an a priori estimate 
of 50% receiving antiviral treatment, the resulting 95% confidence interval, (44-56%) is 





Between December 2008 and December 2012, 350 adults had influenza tests sent from the ED 
which were positive for influenza, of whom 8 left prior to completion of their ED work-up and 
treatment and were excluded from the study.  Of the 342 subjects included in the analysis, 282 
(82%) subjects met 2011 CDC criteria for antiviral treatment and 60 (18%) subjects did not.  
Characteristics of the study subjects and the 2011 CDC criteria are displayed in Table 1.  
Amongst all subjects, 130 (38%) received antiviral treatment from the ED.  Of subjects 
recommended to receive antiviral treatment, 41% (95% CI 36-47%) received antiviral treatment 
in the ED.  Subjects recommended to receive antiviral treatment were more likely to receive ED 
antiviral treatment compared to those who were not recommended to receive antiviral treatment 
(41% versus 23%, p=0.01).  Only 60% of the population fit the CDC definition of ILI.  Subjects 
recommended to receive antiviral treatment were less likely to meet CDC criteria for ILI than 
those who are not recommended to receive antiviral treatment (57% versus 75%, p=0.01).   
 
Among individuals recommended to receive antiviral treatment, we compared those who were 
treated with an antiviral to those not treated with an antiviral as shown in Table 2.  Antiviral 
treatment patterns were variable across influenza seasons as over half of the patients were treated 
during the largest (2009-2010) and smallest influenza seasons (2011-2012), but in the remaining 
seasons, less than half of the patients were treated.  Treatment also varied with the type of 
influenza, as patients that were positive for influenza B positive were less likely to be treated.  
Consistent with previous evidence demonstrating that antivirals are more effective when given 
close to symptom onset, the duration of symptoms was associated with antiviral treatment as 
patients with symptoms less than 48 hours were more likely to receive antiviral treatment.  In 
comparing patient presentation and diagnosis, patients with a clinical diagnosis of influenza were 
more likely to be treated with an antiviral and patients who had a positive influenza test result 
available prior to disposition were more likely to receive antiviral treatment.  Patients with an 
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infiltrate on chest X-ray or those who received antibiotics in the ED were less likely to receive 
ED antiviral treatment for influenza.  Using the Pneumonia Severity Index as a marker of severity 
of disease, there was no association between disease severity and antiviral treatment.  Similarly, 
there was no association between hospital admission and antiviral treatment.  Of the 111 patients 




This study is a retrospective evaluation of influenza testing at a single medical center.  As with 
any retrospective evaluation there exists the potential for missing or false information in the 
medical record.  The testing and treatment patterns at this single tertiary care medical center may 
not represent that of other facilities.  As this study only evaluated patients who had a positive 
influenza, the results are influenced by the provider’s decision to obtain influenza testing.  
Patients in whom providers did not test for influenza either because they did not suspect influenza 
or it would not change their management, are not included in this study and may represent a 
different patient population.  However, as provider diagnosis of influenza and clinical signs and 
symptoms have low sensitivity for influenza, restricting the population to only those with a 
positive influenza test allows for evaluation of patients with confirmed disease. 
 
Although CDC recommendations have remained largely the same over the timeframe of the 
study, some of the details have changed.  The definition of the high risk population has remained 
fairly consistent with the exception the addition of Native American heritage and morbid obesity 
as risk factors in 2011 [4,46,47].  This study included no patients who were of Native American 
heritage.  Of the 6 patients with morbid obesity, all had additional medical conditions which 
would include them in the high risk population.  Hence, all subjects in this study identified as 
high risk according to the 2011 guidelines would have been considered high risk by previous 
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guidelines.  Prior to 2009, the CDC recommended antiviral treatment for individuals with or at 
high risk of influenza-related complications if they had confirmed influenza and treatment was 
started within 48 hours of symptom onset [46].  As evidence demonstrating poor sensitivity of 
rapid influenza tests, and continued antiviral benefit even if started beyond 48 hours from 
symptom onset accumulated, these restrictions were removed in 2009 [47].  This may have 
contributed to the particularly low treatment rates seen in the 2008-2009 influenza season, but 
was consistent for the remaining 4 influenza seasons included in the study.   
 
DISCUSSION 
Despite a growing body of observational studies demonstrating the effectiveness of antiviral 
medications, ED providers do not follow CDC recommendations regarding influenza antiviral 
treatment.  This study further confirms non-adherence with CDC recommendations as only 41% 
of patients with confirmed influenza who meet CDC criteria for recommended antiviral treatment 
received influenza antiviral treatment from the ED.  The reticence of ED clinicians to prescribe 
antivirals has multiple possible explanations including difficulty in confirming the diagnosis of 
influenza, as evidenced by numerous studies which have demonstrated the logical connection 
between increased influenza testing and increased antiviral use [34,41,42].   
 
The current lack of reliable rapid influenza tests make diagnosis and timely treatment of influenza 
challenging, especially in fast-paced treatment settings such as the ED.  Though highly sensitive, 
traditional rt-PCR-based tests take several hours to result, reducing their clinical utility in the ED 
setting.  Rapid antigen-based tests have a much faster turn-around time, but have lower 
sensitivity, ranging from 10-70%, and current CDC guidelines require additional testing in the 
setting of a negative rapid influenza test due to their poor sensitivity [23]. There are several 
emerging molecular-based tests with a more rapid turn-around time of approximately one hour; 
however, these test are not yet in widespread use, and are not available at most EDs.  This study 
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confirms the challenge of obtaining sensitive laboratory results in the typical timeframe of an ED 
visit.  Although all subjects in this analysis were tested for influenza in the ED, only 30% of 
patients recommended to receive treatment had a positive test which resulted while the patient 
was in the ED.  Patients who had a positive test result while they were still in the ED were more 
likely to receive antiviral treatment (63%) than those who did not (46%).  Increased availability 
of sensitive influenza tests which will result in the timeframe of a typical ED visit, could improve 
provider adherence with CDC guidelines. 
 
Given the lack of reliable testing options which yield rapid results, emergency physicians often 
diagnose influenza based on symptoms. Many studies have attempted to validate the use of 
clinical symptoms to diagnose influenza overall showing poor sensitivity and specificity.  One of 
the largest studies showed that a combination of fever and cough had a sensitivity 64% and 
specificity 67% [24].  Two subsequent meta-analyses confirmed that there are no symptoms or 
combination of symptoms which has adequate sensitivity to make informed clinical decisions 
regarding influenza treatment [25,26].  In this retrospective population, only 60% of subjects 
fulfill the CDC criteria for ILI, and patients who are recommended to receive treatment were less 
likely to have classic ILI symptoms than otherwise healthy individuals.  Patients who may benefit 
the most from antiviral treatment (i.e. elderly or immunosuppressed patients), may not mount a 
fever or typical immune response to influenza, making the classic symptoms of ILI less useful in 
this critical population. 
 
The lack of availability of highly-sensitive rapid laboratory tests, coupled with the non-specific 
symptoms with which influenza presents, creates a diagnostic challenge for providers.  This 
uncertainty in the diagnosis of influenza may lead to decreased antiviral treatment.  In this study, 
providers recorded a diagnosis of influenza in 20% of those recommended to receive antiviral 
treatment.  Those with a diagnosis of influenza were more likely to receive antiviral treatment.  
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This uncertainty in diagnosis can be further complicated by the suspicion of an alternate diagnosis 
of bacterial infection.  Though influenza is well known to cause lower respiratory tract disease, 
and the presence of influenza-related pneumonia is an indication for antiviral treatment, an 
infiltrate on a chest X-ray made a patient less likely to receive antiviral treatment.  This suggests 
that the presence of an infiltrate on chest X-ray may have been interpreted as a bacterial 
pneumonia, thus misleading providers from diagnosing and treating influenza.  This theory is 
supported by examining antibiotic use, where patients who received antibiotic treatment in the 
ED were less likely to receive antivirals. 
 
Other factors such as concern for spreading antiviral resistance due to increased antiviral use, or 
belief that antivirals are not effective in preventing influenza-related complications may 
contribute to the lack of adherence with CDC guidelines regarding influenza antiviral treatment.  
The strongest evidence as to the effectiveness of antiviral medications is for admitted patients 
where observational studies show decreased mortality and length of stay associated with antiviral 
use [10,11].  Hence, potential provider concerns regarding antiviral resistance or lack of 
effectiveness should lead to greater treatment of admitted patients, where there is convincing 
evidence of effectiveness, and providers would not likely withhold medication in the name of 
preventing resistance.  However, in this study, patients admitted the hospital were not more likely 
to receive antiviral treatment.  As an additional evaluation of patients with more severe illness, 
we evaluated the relationship between antiviral treatment and the Pneumonia Severity Index, 
which was previously been shown to correlate with the severity of illness in influenza patients 
[45].  In this population, there was no association between antiviral treatment and the Pneumonia 
Severity Index, indicating that the sickest patients were not more likely to receive antiviral 






In summary, there is poor adherence with CDC recommendations on influenza antiviral treatment 
amongst ED patients with laboratory confirmed influenza.  Surprisingly, hospital admission and 
severity of illness are not associated with antiviral treatment.  However, factors associated with 
making a clear influenza diagnosis such as a provider diagnosis of influenza, and a positive 
influenza test result during the ED visit are associated with antiviral treatment.  These factors 
suggest that integrating a sensitive rapid influenza test in to ED care may improve adherence with 









n (column %) 
Recommended 
to Treat* 
n (column %) 
Not Recommended 
to Treat* 
n (column %) 
Number of Subjects 342 282 60 
Age (Years) 37 (23-50) 42 (24-52) 25 (21-35) 
Male Gender 141 (41%) 111 (39%) 30 (50%) 
Race 
      African American 237 (69%) 224 (79%) 49 (82%) 
   White 47 (14%) 39 (14%) 8 (13%) 
   Other 58 (17%) 19 (7%) 3 (5%) 
Influenza Season 
      2008-2009 40 (12%) 31 (11%) 9 (15%) 
   2009-2010 154 (45%) 128 (45%) 26 (43%) 
   2010-2011 78 (23%) 67 (24%) 11 (18%) 
   2011-2012 16 (5%) 56 (20%) 7 (12%) 
   2012-2013 54 (16%) 56 (20%) 7 (12%) 
Type of influenza    
   Influenza A 308 (90%) 261 (93%) 47 (78%) 
   Influenza B 33 (10%) 20 (7%) 13 (22%) 
Diagnosis    
   Influenza-like Illness 206 (60%) 161 (57%) 45 (75%) 
   ED diagnosis of influenza 72 (21%) 57 (20%) 15 (25%) 
Treatment  Criteria    
   Hospital admission 177 (52%) 177 (63%) NA 
   Complications/Pneumonia 54 (16%) 54 (19%) NA 
   Age 65 or greater 19 (6%) 19 (7%) NA 
   Chronic Disease    
      Pulmonary 132 (39%) 132 (47%) NA 
      Cardiovascular 84 (25%) 84 (30%) NA 
      Renal 39 (11%) 39 (14%) NA 
      Hematologic 26 (8%) 26 (9%) NA 
      Metabolic 59 (17%) 59 (21%) NA 
      Neurologic 32 (9%) 32 (11%) NA 
   Immunosuppression 85 (25%) 85 (30%) NA 
   Pregnancy 3 (1%) 3 (1%) NA 
   Morbid Obesity 6 (2%) 6 (2%) NA 
   Resides in Nursing Home 0 (0%) 0 (0%) NA 
   Native American 0 (0%) 0 (0%) NA 
ED treatment    
   Antiviral given in ED 106 (31%) 100 (35%) 6 (10%) 
   Antiviral prescription only 24 (15%) 16 (15%) 8 (13%) 
   Any antiviral treatment from ED 130 (38%) 116 (41%) 14 (23%) 
   Antibiotic given in ED 164 (48%) 152 (54%) 12 (20%) 




Table 2: Potential treatment factors of subjects recommended to receive antiviral treatment 














n (column %) 
p-value 
Number of Subjects 282 116 166  
Influenza Season 
   
 
   2008-2009 31 (11%) 4 (3%) 27 (16%)  
   2009-2010 128 (45%) 62 (53%) 66 (40%)  
   2010-2011 67 (24%) 22 (19%) 45 (27%) 0.001 
   2011-2012 9 (3%) 6 (5%) 3 (2%)  
   2012-2013 47 (17%) 22 (19%) 25 (15%)  
Type of influenza     
   Influenza A 261 (93%) 113 (97%) 148 (89%) 0.009 
   Influenza B 20 (7%) 3 (3%) 17 (10%)  
Diagnosis     
   Influenza-like Illness 161 (57%) 70 (60%) 91 (55%) 0.356 
   ED diagnosis of influenza 57 (20%) 42 (36%) 15 (9%) < 0.001 
Alternate Diagnosis     
   Infiltrate on Chest X-ray 65 (23%) 17 (15%) 48 (29%) 0.005 
   ED diagnosis of pneumonia 54 (19%) 16 (14%) 38 (23%) 0.053 
   Antibiotic treatment in the ED 152 (54%) 49 (42%) 103 (62%) 0.001 
Severity     
   Hospital Admission 177 (63%) 66 (57%) 111 (67%) 0.088 
   Pneumonia Severity Index 
   
 
      I 159 (56%) 66 (57%) 93 (56%)  
      II 66 (23%) 22 (19%) 44 (27%)  
      III 33 (12%) 18 (16%) 15 (9%) 0.518 
      IV 21 (7%) 9 (8%) 12 (7%)  
      V 3 (1%) 1 (1%) 2 (1%)  
Positive influenza test result  
   available before disposition 
84 (30%) 55 (47%) 29 (17%) < 0.001 
Symptoms less than 48 hours 150 (53%) 73 (63%) 77 (46%) 0.007 





Aim 2: Provider Diagnosis of Influenza 
 
INTRODUCTION 
Each year influenza causes significant morbidity and mortality including over 200,000 
hospitalizations and 3,000-49,000 deaths in the United States alone [2,3].  Fortunately, timely 
antiviral treatment can decrease morbidity and mortality in patients at increased risk for, or with 
existing influenza-related complications, and is recommended in these populations by the CDC, 
WHO, and IDSA [4-6].  Specifically, the CDC recommends antiviral treatment for patients with a 
severe or complicated course, those requiring hospitalization, and those at high risk of 
complications, including patients at the extremes of age (<5 years old, >65 years old), residing in 
a chronic care facility, or with specific chronic medical conditions, immunosuppression, 
pregnancy, morbid obesity, or Native American heritage [4].  Antiviral therapy is most effective 
when given close to the time of symptom onset, therefore rapid diagnosis and treatment of 
individuals with influenza and existing or increased risk of complications is essential [18-21].  
Moreover, given the limited number of effective antiviral options, and concerns of increasing 
antiviral resistance, antiviral treatment must also be targeted to those with influenza, who will 
benefit most from treatment.  Hence, accurate diagnosis of influenza virus infections is key to 
providing targeted antiviral treatment. 
 
Diagnosing influenza remains a challenge, especially in the ED where a substantial number of 
patients with influenza and other respiratory infections seek care.  There are currently no reliable 
methods to diagnose influenza in the timeframe of a typical ED visit, leaving emergency 
clinicians to make diagnostic and treatment decisions with limited, insufficient information.  The 
current gold standard influenza test, rt-PCR, typically requires several hours for results.  In an 
attempt to fill the need for rapid diagnosis, several antigen-based rapid influenza tests are in use; 
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however these tests have poor to moderate sensitivity ranging from 10-70%, and current CDC 
guidelines require additional testing in the setting of a negative test [23].  Some laboratories 
utilize DFA, which result in as little as 30-60 minutes, but still have only moderate (50-80%) 
sensitivity [22].  Highly sensitive, molecular-based rapid tests are increasingly available but have 
not yet been widely adopted, particular in the ED setting [48].  
 
Given the lack of access to highly accurate rapid tests, ED clinicians often diagnose influenza 
based on clinical signs and symptoms.  Although many studies have attempted to validate the use 
of clinical signs and symptoms to diagnose influenza, findings indicate overall poor sensitivity 
and specificity.  The CDC created the case definition of ILI as fever equal to or greater than 37.8 
Celsius with either cough or sore throat; however, sensitivity of ILI for influenza is only 55-69% 
[43,49].  One of the largest studies showed that a combination of fever and cough had a 
sensitivity 64% and specificity 67% [24].  Further, two subsequent meta-analyses confirmed that 
there are no combination of signs and symptoms which have adequate sensitivity to make 
informed clinical decisions regarding influenza treatment [25,26].  Hence, in the current ED 
practice environment, accurate diagnosis of influenza remains a challenge. 
 
Accurate diagnosis of influenza is particularly important in patients presenting with 
complications or conditions that increase the risk of influenza-related complications as diagnosis 
will impact decision-making regarding antiviral treatment.  Although a previous ED-based study 
demonstrated that clinician judgment had a poor sensitivity of only 29% (95% CI 18-43%), it 
excluded this crucial population [42].  In this study, the sensitivity and specificity of clinician 
diagnosis and CDC’s definition of ILI compared to PCR were determined in those recommended 
to receive antiviral treatment according to CDC guidelines. Additionally, appropriate use of 







This was a prospective observational cohort study to determine the sensitivity and specificity of 
clinician diagnosis and the CDC criteria for ILI compared to PCR testing for influenza in adult 
ED patients with an acute respiratory illness who met CDC criteria for recommended influenza 
antiviral treatment.  The study was conducted at an urban, university-affiliated tertiary care ED 
with an ED volume of over 60,000 annual patient visits. It was approved by the Johns Hopkins 
Institutional Review Board. 
 
Study Population 
All adult patients presenting to the ED between December 2012 and March 2013 during study 
enrollment hours, with a chief complaint of fever or any respiratory-related symptom, were 
screened by trained, dedicated study coordinators.  Study enrollment hours were Monday through 
Friday from 9am to 5pm during the month of December, and from 9am to 11pm during January, 
February, and March.  Subjects were screened for the following inclusion criteria: 1) 18 years of 
age or older; 2) symptoms of an acute respiratory tract infection defined as new symptoms of 
cough, sinus pain, nasal congestion, rhinorrhea, sore throat, shortness of breath, or fever which 
developed over the previous 2 weeks; and 3) one or more of the following CDC indications for 
influenza treatment: hospital or observation admission, potential influenza related complications 
(i.e. pneumonia), age 65 years old or older, chronic pulmonary disease, cardiovascular disease 
(except hypertension alone), renal disease, hepatic disease, hematologic disease, metabolic 
disorders, neurologic and neurodevelopment conditions, immunosuppression (including that 
caused by medications or HIV infection), pregnant or less than two weeks postpartum, American 
Indians or Alaska natives, morbid obesity (body mass index ≥40), or resident of a chronic-care 
facility.  Patients were excluded if they had prior diagnosis of influenza within the previous 2 
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weeks, did not speak English, were unable to provide informed consent, or were unable to 
provide follow-up contact information. 
 
Study Protocol 
Consenting subjects were asked to complete a written structured questionnaire regarding basic 
demographics, current symptoms, and past medical history.  A nasopharyngeal swab was 
collected from each patient, placed in viral transport media (MicroTest M4RT, Remel, Lenexa, 
KS), aliquoted, frozen to minus 70 degrees, and stored for subsequent influenza testing with a 
PCR assay (Prodesse ProFlu+, Hologic Gen-probe Incorporated, San Diego, CA).  ED providers 
were blinded from influenza PCR test results. 
 
In order to obtain the clinician diagnosis, the ED provider for each subject was asked to respond 
“Yes” or “No” to the following question: “Do you think this patient has influenza?”.  Study 
coordinators were instructed to pose this question to providers as close to the time of subject 
disposition from the ED as possible but prior to the result of provider-requested rapid influenza 
testing (antigen detection by fluorescence microscopy).   
 
Following the ED visit, data were extracted from the hospital’s electronic medical record (EMR), 
which included both ED and inpatient documentation.  Data were entered into a standardized, 
closed entry, Microsoft Excel (Microsoft Corporation, Redmond, Washington) database and 
included initial ED vital signs, ED laboratory and culture data, ED radiologic findings, ED 
management, disposition from the ED, and final (ICD 9) ED diagnoses. 
 
Measurements 
Presence or absence of ILI was based upon the CDC criteria for ILI of a fever equal to or greater 
than 37.8 Celsius with either cough or sore throat [43].  Antibiotic and antiviral administration 
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was recorded as either none, administered in the ED, or discharged with a prescription. A subject 
was considered to have received ED antiviral or antibiotic treatment if they were administered an 




Data were analyzed using basic descriptive statistics including proportions and percentages for 
dichotomous variables, median and interquartile range for continuous data, sensitivity, specificity, 
and likelihood ratios.  Data were analyzed using Stata Statistical Software: Release 11 (Stata 
Corp LP, 2009. College Station, TX). 
 
RESULTS 
Of the 303 subjects enrolled, 270 (89%) were included in the final analysis. Thirty-three patients 
who were initially enrolled but not included in the final analysis were: 1 patient found on detailed 
history not to meet all inclusion criteria; 11 who did not have PCR testing performed and; 21 who 
did not have a clinical provider diagnosis response completed prior to the return of provider-
requested influenza testing, or prior to patient disposition from the ED.   
 
Table 3 displays the basic demographics of the study subjects, as well as indications for potential 
antiviral treatment according to the CDC recommendations.  The most common CDC indications 
for antiviral treatment were chronic pulmonary disease (64%), hospital admission (43%), chronic 
metabolic disease such as diabetes mellitus (30%), and immunosuppression (26%).  Recent 
influenza vaccination was reported by 146 (54%) subjects, including 15 (36%) influenza positive 




Of the 270 subjects analyzed, 42 (16%, 95% CI 11%-20%) had influenza according to PCR 
testing.  Of subjects with confirmed influenza, 27 (64%) had Influenza A and 15 (36%) had 
Influenza B.  Clinicians correctly diagnosed 15/42 subjects found to have influenza by PCR, and 
incorrectly diagnosed influenza in 50/228 subjects who were negative for influenza by PCR 
(Table 4).  Clinical diagnosis therefore had a sensitivity of 36% (95% CI 22-52%) and a 
specificity of 78% (95% CI 72-83%).  For patients who presented within 48 hours of symptom 
onset, the sensitivity of clinician diagnosis was 39% (95%CI 14-69%).  Similarly, the symptoms 
of ILI correctly identified 13/42 subjects with PCR confirmed influenza, and incorrectly 
identified 27/228 subjects who were negative for influenza by PCR (Table 4).  Thus, ILI had an 
overall sensitivity of 31% (95%CI 18-47%), and a sensitivity of 46% (95%CI 19-75%) for 
patients presenting within 48 hours of symptom onset (Table 5).  Only 18 patients had an EMR 
recorded diagnosis of influenza, which had a sensitivity of 26% (95% CI 14-42%) and specificity 
of 97% (95% CI 94-99%).   
 
In this population of patients recommended to receive antiviral treatment according to CDC 
guidelines, only 15 (36%) subjects with PCR-confirmed influenza received antiviral treatment 
from the ED, with 11 (26%) starting the medication while still in the ED.  Interestingly, 22 (52%) 
of subjects with PCR-confirmed influenza received antibiotic treatment from the ED, 4 of whom 
had an infiltrate on chest X-ray and a corresponding diagnosis of pneumonia.  Among the 13 
patients who had influenza and symptoms for less than 48 hours, only 6 (46%) received ED 
antiviral treatment, 3 (23%) of whom initiated treatment while still in the ED.   
 
LIMITATIONS 
This study was performed at a single academic medical center, thus potentially limiting its 
generalizability to other geographic areas and practices.  Another potential limitation is the 
method of obtaining the clinician diagnosis.  This study sought to determine the accuracy of 
27 
 
clinician diagnosis of influenza in the absence of ancillary influenza testing.  ED clinicians were 
queried prior to the result of routine (i.e., provider requested) influenza testing if it was 
performed.  We obtained ED clinician diagnosis as close as possible to final patient disposition so 
the clinician would have the full benefit of ancillary tests such as basic laboratory tests and 
diagnostic imaging.  It is possible that the clinician obtained additional clinical information (e.g. 
new fever, and/or radiographic or other laboratory testing) after giving their study-related clinical 
diagnosis, which may have affected their diagnosis.  However, the EMR diagnosis of influenza, 
which was recorded after clinicians had all available information, had similar or even lower 
sensitivity (26%; 95% CI 14-42%) than the reported clinician diagnosis (36%; 95% CI 22-52%). 
 
DISCUSSION 
This study evaluated the sensitivity and specificity of ED clinician diagnosis of influenza in adult 
ED patients who are recommended to receive antiviral treatment according to CDC guidelines.  
Overall, clinical diagnosis of influenza by ED clinicians had poor sensitivity and specificity.  The 
low sensitivity (36%; 95% CI 22-52%) is similar to that reported previously by Stein et al (29%) 
[42]. Unlike Stein and colleagues however, the sensitivity of clinical diagnosis did not improve in 
the subset of patients who presented with less than 48 hours of symptoms. The specificity for 
clinician diagnosis in this study (78%; 95% CI 72-83%) was lower than that found in previous 
reports (92%; 95% CI 87-95%).  The reduced specificity is likely related to the relatively higher 
level of medical complexity of our study population.  The population in this study included those 
with current pneumonia or a history of pulmonary disease, which may have led to an increase in 
false positive influenza diagnoses. 
 
Clinicians may rely on CDC’s definition of ILI when considering the diagnosis of influenza in 
clinical practice.  Although previous studies have demonstrated that the CDCs definition of ILI 
has a sensitivity of 55-69% in a broad population, our evaluation found a substantially lower 
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sensitivity (31%; 95% CI 18-47%) [49].  The decreased sensitivity of ILI is likely related to the 
patient population which included several patient groups that may not be able to mount an 
appropriate immune response or fever (e.g. immunosuppressed, elderly).  This is consistent with 
previous findings that the sensitivity of symptoms such as cough and fever for diagnosing 
influenza are decreased in elderly patients (30%) compared to the larger population (64%) 
[24,25,50].  Thus, in those recommended to receive antiviral treatment in whom diagnosis is most 
essential, the classic symptoms of ILI are less reliable. This finding has important implications for 
clinical outcomes.  
 
Previous work has demonstrated poor compliance with CDC recommendations regarding 
antiviral treatment.  Hsieh et al. found that only 50% of ED patients with a final ED diagnosis of 
influenza, who met CDC criteria for recommended antiviral treatment, actually received it [31].  
As this evaluation demonstrates, ED clinicians’ diagnosis of influenza is a poor proxy for 
influenza.  In our evaluation, the final ED diagnosis of influenza (as recorded in the electronic 
medical record) is only 26% sensitive for PCR-confirmed influenza.  Thus, the actual compliance 
with CDC recommendations is likely to be even lower than previous estimates, because those 
estimates do not take into account patients who had influenza, but were not diagnosed due to the 
poor sensitivity of clinicians’ diagnosis.  This is confirmed by the current study, which 
demonstrates that only 36% of subjects with laboratory confirmed influenza, from a population of 
those recommended to receive antiviral treatment according to CDC guidelines, received antiviral 
treatment.  In fact, a patient with influenza was more likely to receive antibiotic (52%) than 
antiviral (36%) treatment.   
 
Previous literature has shown that antiviral treatment is most effective when administered closer 
to the time of symptom onset [18-21].  Previous recommendations to initiate antiviral treatment 
within 48 hours was recently extended in the CDC guidance, especially in patients with influenza 
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related complications, as multiple observational studies have shown that antiviral treatment up to 
5 days from symptom onset decreased mortality in admitted patients [11-13].  Despite this change 
in recommendations, many providers consider treatment only if the patient has had under 48 
hours of illness, especially in non-hospitalized patients.  In our study population, 33% of the 
patients presented in less than 48 hours, of whom 31% had laboratory confirmed influenza.  Of 
those patients, 46% received antiviral treatment. 
 
In addition to undertreating subjects with influenza, this study demonstrated antiviral 
overtreatment in patients without influenza, which raises concerns of increasing antiviral 
resistance.  Eleven percent of patients who did not have influenza received antiviral treatment.  
Of the 40 patients who received an antiviral, more of them had a negative influenza test (25) than 
a positive test (15).  Due to the lack of rapid accurate influenza testing, the CDC recommends 
initiating antiviral treatment for all patients with existing or increased risk of influenza related 
complications in whom influenza suspected, regardless of influenza testing [4,28].  These 
recommendations are based on the assumption that the prolonged time to result of accurate 
conventional or batched molecular diagnostic tests will significantly delay antiviral treatment, 
which is most effective when given close to the time of symptom onset.  Antigen-based rapid 
tests have poor sensitivity requiring additional testing if negative, also potentially increasing the 
time to antiviral treatment.  Though these recommendations are well founded, they result in 
extensive overtreatment.  Both over and under treatment could be substantially improved by 
integrating highly sensitive, molecular-based rapid tests into current clinical care. 
 
CONCLUSION 
Overall, this study evaluated the diagnosis and treatment of influenza in adult ED patients who 
met CDC criteria for recommended antiviral treatment.  In this target population, both ED 
clinician diagnosis, and the classic CDC definition of ILI have poor sensitivity for influenza.  ED 
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management of influenza demonstrates both under-treatment, in those with confirmed influenza 
(36%), and overtreatment in those without influenza (11%).  Clinician’s inability to appropriately 
administer antivirals is likely related to the underlying challenges of accurate diagnosis.  
Integrating new highly-sensitive rapid diagnostic tests for influenza could improve accuracy of 








n (column %) 
Influenza 
Positive 
n (column %) 
Influenza 
negative 
n (column %) 
Number of Subjects 270 42 228 
Age (Years) 50 (38-58) 43.5 (32-55) 50.5 (39.5-58) 
Male Gender 110 (41%) 15 (36%) 95 (42%) 
Race    
   African American 220 (81%) 34 (81%) 186 (82%) 
   White 41 (15%) 5 (12%) 36 (16%) 
   Other 5 (1.9%) 1 (2.4%) 4 (1.8%) 
CDC Guidelines (indication for antiviral treatment) 
   Hospital admission 117 (43%) 16 (38%) 101 (44%) 
   Complications/Pneumonia 32 (12%) 4 (9.5%) 28 (12%) 
   Age 65 or greater 37 (14%) 5 (12%) 32 (14%) 
   Chronic Disease    
      Pulmonary 172 (64%) 17 (40%) 155 (68%) 
      Cardiovascular 62 (23%) 5 (12%) 57 (25%) 
      Renal 31 (11%) 6 (14%) 25 (11%) 
      Hematologic 22 (8.1%) 4 (9.5%) 18 (7.9%) 
      Metabolic 82 (30%) 11 (26%) 71 (31%) 
      Neurologic 26 (9.6%) 7 (17%) 19 (8.3%) 
   Immunosuppression 71 (26%) 13 (31%) 58 (25%) 
   Pregnancy 1 (0.4%) 1 (2.4%) 0 (0%) 
   Morbid Obesity 23 (8.5%) 3 (7.1%) 20 (8.8%) 
   Resides in Nursing Home 6 (2.2%) 0 (0%) 6 (2.6%) 
   Native American 0 (0%) 0 (0%) 0 (0%) 
Influenza Vaccination 146 (54%) 15 (36%) 131 (57%) 
Symptoms less than 48 hours 88 (33%) 13 (31%) 75 (33%) 









n (column %) 
Influenza 
Positive 
n (column %) 
Influenza 
Negative 
n (column %) 
Number of Subjects 270 42 228 
Diagnosis    
   Clinician diagnosis of influenza 65 (24%) 15 (36%) 50 (22%) 
   Influenza-like Illness 40 (15%) 13 (31%) 27 (12%) 
   Final ED diagnosis of influenza 18 (6.6%) 11 (26%) 7 (3.1%) 
ED treatment    
   Antiviral given in ED 31 (11%) 11 (26%) 20 (8.8%) 
   Antiviral prescription only 9 (3.3%) 4 (9.5%) 5 (2.2%) 
   Any ED antiviral treatment 40 (15%) 15 (36%) 25 (11%) 

















Symptom onset    
< 48 hours 
n=88 
Symptom onset 
> 48 hours 
n=182 
Influenza Prevalence 16% (11-20%) 15% (8-24%) 16% (11-22%) 
Clinician Diagnosis    
   Sensitivity 36% (22-52%) 39% (14-69%) 35% (18-54%) 
   Specificity 78% (72-83%) 83% (72-90%) 76% (68-82%) 
   Positive Likelihood Ratio 1.63 (1.01-2.62) 2.22 (0.95-5.17) 1.43 (0.80-2.53) 
   Negative Likelihood Ratio 0.82 (0.65-1.04) 0.74 (0.48-1.12) 0.86 (0.65-1.14) 
Influenza-like Illness    
   Sensitivity 31% (18-47%) 46% (19-75%) 24% (10-43%) 
   Specificity 88% (83-92%) 88% (78-94%) 88% (82-93%) 
   Positive Likelihood Ratio 2.61 (1.47-4.64) 3.85 (1.65-8.99) 2.05 (0.94-4.46) 
   Negative Likelihood Ratio 0.78 (0.64-0.96) 0.61 (0.37-1.02) 0.86 (0.70-1.06) 
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Aim 3: Performance of Rapid Molecular Influenza Testing 
 
INTRODUCTION 
Influenza is responsible for over 200,000 hospitalizations and 3,000-49,000 deaths in the United 
States each year [2,3].  However, morbidity and mortality associated with influenza infections 
could be decreased by timely antiviral treatment.  The CDC, WHO and IDSA recommend 
antiviral treatment for patients with a severe or complicated course, namely those requiring 
hospitalization, as well as those at high risk of complications, including patients at the extremes 
of age (<5 years old, >65 years old), patients residing in a chronic care facility, and those with 
specific chronic medical conditions, immunosuppression, pregnancy, morbid obesity, or Native 
American heritage [4-6].  Unfortunately, compliance with these guidelines remains low, partially 
due to the challenge of timely and accurate diagnosis of influenza infection [28,31]. 
 
The majority of patients with influenza and other respiratory viruses seek care in episodic 
outpatient care settings such as EDs or other urgent and primary care settings, where rapid 
diagnosis and treatment is critical [40].  Due to non-specific symptoms, provider clinical 
diagnosis of influenza has low sensitivity, leading providers to rely on diagnostic testing for an 
accurate influenza diagnosis [42].  Most commercially available real-time polymerase chain 
reaction (rt-PCR) tests are typically run in batch, and require several hours to complete, delaying 
results. The current antigen detection tests are rapid, but have poor to moderate sensitivity, 
ranging from 10-70% [23].  Molecular-based rapid influenza tests, such as the GeneXpert Xpert 
Flu (Cepheid, Sunnyvale, CA, USA), may have clinical utility by filling this diagnostic gap, since 
it has a reported time to result of approximately 80 minutes and significantly higher sensitivity 




The majority of previous performance evaluations of Xpert Flu demonstrate an overall high 
sensitivity (90-100%) and specificity (99-100%) for influenza A (5 out of 7 studies), Influenza A 
2009 H1N1 (5 out of 8 studies), and Influenza B (4 out of 6 studies) [27,51-58].  Four notable 
exceptions include Popowich et al., who report moderate sensitivity (87%) for H1N1 [53]; Salez 
et al., who initially reported a lower sensitivity for influenza B (81%) [51], but later found 
improved sensitivity (95%) with a newer version of the assay [52]; Li et al., who reported lower 
sensitivity across all influenza types [A (79%), A 2009 H1N1 (75%) and B (77%)] [57]; and 
Pierro et al who found extremely low sensitivity for influenza A (38%) and moderate sensitivity 
for 2009 H1N1 (86%) [58].  Each of these previous reports, with the exception of Pierro et al., 
fails to clearly identify and define the test population in which the test was evaluated.  Pierro et al, 
used samples from hospitalized patients, but demonstrated markedly different results from the 
previous evaluations and was limited by a small sample size (N=60).  Thus the performance of 
rapid PCR-assays, such as Xpert Flu, in the recommended target population of patients with 
existing or at increased risk of influenza related complications and undifferentiated respiratory 
symptoms, remains unclear, particularly in the ED setting. 
 
Prior to integration into routine clinical use, the clinical performance of Xpert Flu in the target 
population requires evaluation.  Though clinicians in the outpatient episodic care setting may test 
an array of patients, accurate rapid influenza testing with Xpert Flu test would be most important 
in patients where the test result would impact clinical management, namely those who meet CDC 
criteria for antiviral therapy and are at risk for potential influenza related complications.  Several 
of these conditions, such as advanced age and pneumonia, have been reported to be associated 
with decreased sensitivity of rapid antigen-based testing, highlighting the importance of 
evaluating Xpert Flu in this population [59].  In order to fully translate molecular-based rapid 
testing into clinical practice, we prospectively evaluated the sensitivity and specificity of Xpert 
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Flu in adult ED patients with an acute undifferentiated respiratory illness, who meet CDC criteria 




Study population and sample collection 
Adult ED patients with an undifferentiated acute respiratory illness who met CDC criteria for 
recommended influenza antiviral treatment at an urban, university-affiliated tertiary care ED were 
prospectively enrolled between December 2012 and March 2013.  Enrolled subjects met the 
following inclusion criteria: 1) 18 years of age or older; 2) symptoms of an acute respiratory tract 
infection, defined as new symptoms of cough, sinus pain, nasal congestion, rhinorrhea, sore 
throat, shortness of breath, or fever which developed over the previous 2 weeks; and 3) one or 
more of the following CDC indications for influenza treatment: hospital or observation 
admission, potential influenza related complications (i.e. pneumonia), age 65 years old or older, 
chronic pulmonary disease, cardiovascular disease (except hypertension alone), renal disease, 
hepatic disease, hematologic disease, metabolic disorders, neurologic and neurodevelopment 
conditions, immunosuppression (including that caused by medications or HIV infection), 
pregnant or less than two weeks postpartum, American Indians or Alaska natives, morbid obesity 
(body mass index ≥40), or resident of a chronic-care facility.  Patients were excluded if they had 
prior diagnosis of influenza within the previous 2 weeks, did not speak English, were unable to 
provide informed consent, or were unable to provide follow-up contact information.   
 
Following written consent, as approved by the Johns Hopkins University institutional review 
board (IRB), subjects completed a questionnaire detailing their current symptoms, past medical 
history, and basic demographics.  A nasopharyngeal swab was collected and placed in viral 
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transport media (MicroTest M4RT, Remel, Lenexa, KS, USA).  Following collection, viral 
transport media was aliquoted, and stored at -70°C for subsequent testing. 
 
Molecular Testing 
To eliminate the variable of elapsed time between sample collection and test performance, all 
samples were aliquoted into three tubes, stored frozen, and tested after a single freeze thaw. 
Testing by ProFlu+ (Hologic Gen-probe Incorporated, San Diego, CA, USA) and Xpert Flu 
(Cepheid, Sunnyvale, CA) was performed according to manufacturers’ instructions (with the 
exception of samples with indeterminate Xpert Flu results) after enrollment was complete 
[60,61].  All testing was performed in a blinded fashion. Samples with indeterminate Xpert Flu 
results were not re-tested due to volume constraints; these samples were omitted from the final 
analysis. Discordant samples were evaluated using RT-PCR/ESI-MS via the PLEX-ID (Abbott 
Laboratories, Abbott Park, IL) per manufacturer instructions.  Nucleic acid extraction was 
performed utilizing the Arrow Viral NA kit (Diasorin, Inc. Stillwater, MN), and extracted 
nasopharyngeal samples were amplified and analyzed utilizing the PLEX-ID RVS 2.5 kit  as 




For the primary analysis, Prodesse ProFlu+ was considered the comparative standard.  A similar 
subgroup analysis was performed evaluating patients with the highest acuity illness (those 
admitted to the hospital).  In a secondary evaluation, discordant results were further evaluated 
with RT-PCR/ESI-MS with the two tests in agreement considered as the comparative standard.  
Data were analyzed utilizing basic descriptive statistics including proportions and percentages for 
dichotomous variables, median and interquartile range for continuous data, sensitivity, specificity, 
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and likelihood ratios.  Data were analyzed using Stata Statistical Software: Release 11 (StataCorp 
LP, 2009. College Station, TX). 
 
RESULTS 
Of 303 subjects enrolled, 281 had sufficient data to be included in the final analysis.  Of the 22 
excluded subjects: 1 subject was found not to meet full inclusion criteria, 11 did not have ProFlu+ 
testing performed, 5 did not have Xpert Flu testing, and 5 had Xpert Flu tests which resulted in an 
error code.  Among the 281 subjects included in the final analysis, 126 (44%) were admitted to 
the hospital.  Additional details regarding the included subjects and the criteria for CDC 
recommended antiviral treatment are listed in Table 6. 
 
Of 281 subjects, 43 (15%) were positive for influenza by ProFlu+, of which 28 were positive for 
Influenza A and 15 positive for Influenza B.  Compared to ProFlu+, Xpert Flu had a sensitivity of 
95.3% (95% CI 84.2-99.4) overall, 96.4% (95% CI 81.7-99.9%) for influenza A, and 93.3% (95% 
CI 68.1-99.8%) for influenza B (Table 7).  Although Xpert Flu also detects 2009 H1N1, none of 
the samples were positive for influenza A, 2009 H1N1.   
 
Two discordant results were obtained for influenza A and influenza B. For both viruses, one 
sample was positive by ProFlu+ but negative by Xpert Flu, and one sample was positive by Xpert 
Flu and negative by ProFlu+.  Table 8 displays the concordant and discordant results.  Discordant 
sample testing with RT-PCR/ESI-MS agreed with ProFlu+ testing with one exception; one 
sample was positive for influenza A by ProFlu+, negative for influenza A by Xpert Flu, and 
negative for influenza A by PLEX-ID.  Using an operational gold standard definition of two tests 
in agreement, Xpert Flu had an overall sensitivity of 97.6% (95% CI 87.4-99.9%) and specificity 
of 99.2% (95% CI 97.0-99.9%).  For Influenza A, the sensitivity of Xpert Flu was 100% (95% CI 
87.2-100%) and specificity was 99.6% (95% CI 97.8-100%). 
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Restricting the comparison to the patients with the highest acuity of illness, the 126 subjects who 
were admitted to the hospital, Xpert Flu had 100% sensitivity and specificity for both influenza A 
[sensitivity 100%, 95%CI 76-100%; specificity 100%, 95% CI 97-100%] and influenza B 
[sensitivity 100%, 95%CI 57-100%; specificity 100%, 95% CI 97-100%].  That is, all 12 subjects 




This evaluation of Xpert Flu was performed in a single, inner-city ED, and did not include 
otherwise healthy patients or children, thus potentially reducing the generalizability to all patients 
in various geographic locations.  Additionally, of the 286 Xpert Flu tests performed, 5 (1.7%) 
resulted in an error code, leading to an indeterminate result.  Manufacturer instructions state that 
these tests are to be repeated, which was not performed in this study due to inadequate sample 
volume.  Although errors were low in this study (1.7%), delayed results can subsequently impact 
diagnosis and care.   
 
DISCUSSION 
We evaluated the clinical performance of Xpert Flu in adult ED patients with an acute 
undifferentiated respiratory illness, who met CDC criteria for recommended antiviral treatment.  
This is the first time this rapid diagnostic test has been evaluated in a high acuity ED population, 
where undifferentiated patients are evaluated and treated.  In this high acuity target population, 
Xpert Flu had an overall sensitivity of 95.3% (95% CI 84.2-99.4) and specificity of 99.2% (95% 
CI 97.0-99.9%) when compared to ProFlu+.  Similar high sensitivity and specificity was seen for 
both influenza A [sensitivity 96.4% (95% CI 81.7-99.9%)] and influenza B [sensitivity 93.3% 
(95% CI 68.1-99.8%)].  Using an operational gold standard of two tests in agreement, the 
sensitivity of Xpert Flu increased to 97.6% (95% CI 87.4-99.9%) overall and 100% (95% CI 
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87.2-100%) for influenza A.  Integration of this rapid high sensitivity diagnostic test into ED 
practice for influenza could improve provider decision making and subsequent patient 
management. 
 
The observed sensitivity and specificity of Xpert Flu in this high acuity ED population was 
similar to what has been reported by several previous studies performed in a more general patient 
population [27,51-56].  From a clinical viewpoint, diagnosing influenza and initiating antiviral 
treatment in the admitted population is most critical, as antivirals have shown substantial benefit 
in this population including a reduction in mortality [11-13].  One previous study demonstrated 
poor performance of Xpert Flu amongst hospitalized patients; however, our study showed 
excellent performance amongst the subpopulation of admitted patients with 100% sensitivity and 
specificity [58].  This previous evaluation used a PCR-based, laboratory developed test as a 
comparator, which may have been less accurate than the FDA approved Prodesse ProFlu+ assay 
used in this evaluation, resulting in the observed difference in sensitivities.  
 
CONCLUSION 
Overall, when prospectively evaluated in a population of undifferentiated ED patients with 
existing or at increased risk of influenza related complications, Xpert Flu demonstrated high 
sensitivity and specificity.  Overall sensitivity compared to Prodesse ProFlu+ was 95.3% (95% CI 
84.2-99.4) with similar high sensitivities for influenza A [96.4% (95% CI 81.7-99.9%)] and 
influenza B [93.3% (95% CI 68.1-99.8%)].  Specificity was 99-100% both overall, and for 
influenza A and influenza B individually.  When evaluating a subpopulation of high acuity 
patients who were subsequently admitted for inpatient hospitalization, Xpert Flu had an overall 
sensitivity and specificity of 100%.  With a demonstrated high level of sensitivity and specificity 
in a clinical ED population, and a rapid turn-around time of 80 minutes, Xpert Flu has significant 
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potential to aid clinicians working in episodic care settings such as EDs or urgent care centers 
where rapid influenza diagnosis and management can be challenging.  
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Table 6: Aim 3 Subject Characteristics 
 
n (column %) 
Number of Subjects 281 
Age (Years) 50 (38-58) 
Male Gender 119 (42%) 
Race  
   African American 228 (81%) 
   White 44 (15%) 
   Other 9 (3.2%) 
CDC Guidelines for antiviral treatment 
   Hospital admission 123 (44%) 
   Complications/Pneumonia 19 (6.8%) 
   Age 65 or greater 39 (14%) 
   Chronic Disease  
      Pulmonary 176 (63%) 
      Cardiovascular 64 (23%) 
      Renal 32 (11%) 
      Hematologic 23 (8.2%) 
      Metabolic 70 (25%) 
      Neurologic 25 (8.9%) 
   Immunosuppression 72 (26%) 
   Pregnancy 1 (0.4%) 
   Morbid Obesity 25 (8.9%) 
   Resides in Nursing Home 7 (2.5%) 
   Native American 0 (0%) 





























Influenza Prevalence 15% (11-20) 10% (6.7-14.1) 5.3% (3.2-8.7) 
Test Characteristics    
   Sensitivity 95.3 (84.2-99.4) 96.4 (81.7-99.9) 93.3 (68.1-99.8) 
   Specificity 99.2 (97.0-99.9) 99.6 (97.8-100) 99.6 (97.9-100) 
Likelihood ratios    
   Positive 113 (28.5-452) 244 (35-1727) 248 (35-1764) 
   Negative 0.05 (0.01-0.18) 0.04 (0.01-0.25) 0.07 (0.01-0.45) 
Predictive Value    
   Positive 95.3 (84.2-99.4) 96.4 (81.7-99.9) 93.3 (68.1-99.8) 
   Negative 99.2 (97.0-99.9) 99.6 (97.8-100) 99.6 (97.9-100) 
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Influenza A Influenza B Negative 
Influenza A 27 0 1* 28 
Influenza B 0 14 1
†
 15 
Negative 1* 1* 236 238 
Total 28 15 238 281 
 
* On discordant analysis, sample was negative for influenza by PLEX-ID 
 




Aim 4: Cost Utility of Influenza Diagnosis and Management 
 
INTRODUCTION 
Each year, influenza affects approximate 5-20% of the United States population causing over 
200,000 hospitalizations and 3,000 – 49,000 deaths [1-3].  Fortunately, the past 15 years has 
brought both new antiviral medications and increasing evidence of their effectiveness in specific 
populations.  While the benefit of treatment is questionable in healthy individuals, evidence 
supports antiviral use for patients considered at increased risk for, or those with evidence of 
existing complications, and routine use in those populations is recommended by the CDC, the 
WHO and IDSA [4-6].  Recent CDC guidelines recommend antiviral treatment specifically for 
patients with a severe or complicated clinical course, requiring hospitalization, or considered at 
high risk for influenza complications – including those under 2 years old or 65 years of age or 
above, residing in a chronic care facility, with a chronic medical condition, pregnant or morbidly 
obese [4].  Antiviral medications are currently recommended to be given within 48 hours of 
symptom onset, and appear to have increased effectiveness when given closer to the time of 
symptom onset [18-21].  Despite the evidence that shortening the time between symptom onset 
and antiviral administration results in improved outcomes, practical ability to diagnose and treat 
influenza within this 48 hour time frame is difficult due to timing of patient presentation, 
medication costs, and lack of reliable rapid diagnostic tools. 
 
In an attempt to fill the need for expediting definitive diagnosis, several rapid influenza tests have 
been developed.  Previous antigen-based assays have been limited by moderate to poor 
sensitivities ranging from 10-70%, and current CDC guidelines accordingly require additional 
testing in the setting of a negative rapid influenza test [23].  Given the lack of high performance 
tests that yield rapid results, physicians frequently make a presumptive diagnosis of influenza 
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based on clinical presentation.  Previous studies which have attempted to validate the use of 
clinical symptoms to diagnose influenza however, have demonstrated overall poor sensitivity and 
specificity.  As example, one of the largest studies showed that a combination of fever and cough 
had a sensitivity of 64% and a specificity of 67% [24].  New molecular-based rapid influenza 
tests use PCR-based detection, yield results in 80 minutes, and have recently obtained FDA 
approval for use in clinical settings.  Previous validation studies performed in comparison to a rt-
PCR gold standard report a sensitivity of 91.2% (95% CI: 85.1-95.4) and specificity of 99.4% 
(95% CI: 96.7-100) [27].  Although promising, and with significantly improved performance 
relative to current rapid influenza diagnostic tests seen in clinical settings, molecular-based rapid 
tests have not yet been integrated into clinical practice, largely due to concerns over the clinical 
utility of testing relative to existing approaches, and the associated increased cost. 
 
The majority of the cost-effectiveness analyses of influenza treatment have focused on healthy 
adults.  These studies often conclude that the most cost effective strategy is to treat all patients 
with antiviral medications, driven largely by a 1-2 day reduction in symptoms and decrease in lost 
work costs [35,36].  Cost-effectiveness studies examining patients at increased risk of influenza 
complications have more varied outcomes which depend on influenza prevalence.  When the 
prevalence of influenza is low, treating influenza based on the result of an influenza test is often 
the most cost effective method; however with increasing influenza prevalence, treating all 
patients with suspected influenza without testing becomes most cost effective [37,38].  When 
considering influenza testing, these studies have considered the accurate but expensive gold 
standard rt-PCR testing, or the less-expensive but inaccurate older antigen-based rapid testing.  
The emergence of new accurate molecular-based rapid tests, with a more moderate price and 
improved accuracy could potentially shift the cost-utility balance of influenza testing.   
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Previous cost-effectiveness studies evaluating influenza testing in high risk patients have 
restricted evaluation of those patients with ILI, most commonly defined as fever with cough or 
sore throat [35-38].  Limiting the population of included patients to those with ILI, which has 
been shown to have relatively poor sensitivity and specificity for influenza, provides an 
incomplete analysis as it does not accurately reflect the entire influenza population which may 
benefit from influenza testing and treatment in practice.  A more comprehensive appreciation of 
the cost-effectiveness of influenza testing and treatment requires inclusion of a population with 
the broader criteria of acute onset respiratory or febrile illness, to ensure maximal inclusion of 
influenza patients and reflect the entire population that may benefit from testing and/or antivirals.  
Additionally, there remains limited evidence of the cost-effectiveness of influenza testing and 
treatment in more acute care settings such as the ED where the overall patient acuity mix is 
higher with increased rates of hospital admission, and hence increased rates of influenza-related 
complications and death, additionally impacting the balance between influenza testing and 
treatment. 
 
We sought to determine the relative cost-effectiveness of influenza testing and treatment 
strategies for adults who present to the ED with an acute respiratory illness and meet 2011 CDC 
criteria for recommended influenza treatment.  We performed an incremental evaluation of four 
separate influenza testing and antiviral treatment regimens using a cost-utility based approach: 1) 
Treat none, 2) Treat based on provider judgment, 3) Treat based on results of a molecular-based 









We constructed a cost-utility decision analysis model using TreeAge Pro (TreeAge Software, Inc.) to 
make an incremental comparison among 4 influenza testing and antiviral treatment strategies: 1) 
Treat none, 2) Treat based on provider judgment, 3) Treat based on results of a molecular-based 
rapid diagnostic test, and 4) Treat all.  This model considered patients presenting to the ED with 
symptoms of an acute respiratory infection who, if positive for influenza, would be recommended to 
receive antiviral treatment according to 2011 CDC guidelines; namely patients who are at risk or 
potentially have influenza-related complications.  The analysis employed a societal perspective.  To 
account for potential differences in mortality between treated and untreated influenza patients, we 
considered a lifetime horizon and discounted effects at 3% as recommended by the US Panel on 
Cost-Effectiveness in Health and Medicine [63].   
 
Sensitivity analysis of the assumptions made in the base model were evaluated using a series of one-
way sensitivity analyses displayed in a tornado diagram to highlight the relative impact of potential 
variation in each of these selected variables.  In addition, we explored a range of influenza 
prevalence, as prevalence varies throughout the influenza season and has previously been shown to 
have a significant impact on cost-utility.  Overall robustness of the conclusions based on the model 
was estimated via a probabilistic sensitivity analysis using a Monte Carlo simulation.  This 
simulation used the stated variable ranges included in the one-way sensitivity analysis as well as 95% 
confidence intervals or inter-quartile ranges for the included variables as available.  To interpret the 
results of the Incremental Cost-effectiveness Ratios (ICER) obtained from this analysis we adhered 
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to the generally accepted willingness to pay threshold of $50,000 per Quality Adjusted Life Year 
(QALY) [64]. 
 
Data and Assumptions 
Influenza Prevalence 
The decision analysis model, as shown in Figure 2, assumed the same influenza prevalence for each 
of the 4 potential treatment strategies.  Although influenza prevalence varies throughout the season, 
the base prevalence of influenza used in this study (0.20), reflects the average prevalence of influenza 
amongst patients presenting to the ED with an acute respiratory infection between January and 
March [42].  Previous cost-effectiveness analyses have used the influenza prevalence in patients 
presenting with ILI (fever and cough or sore throat), a more rigorous criteria which increases 
prevalence, but also excludes one third of the patients with influenza [24,38].  Thus, a broader 
definition of acute respiratory virus is likely a more accurate definition of the desired testing 
population.  In order to fully evaluate the cost-utility of the included testing and treatment options, 
we performed a secondary analysis over a large range of the potential prevalence of influenza: 0 to 
0.6. 
 
Patients who did not have influenza were not evaluated further as influenza testing or treatment 
would have no further impact on their care or outcomes.  The only potential difference in the non-
influenza patient’s medical management would be due to side effects of the influenza antiviral 
medications.  However, these medications have mild side effects which only very rarely would 
require additional medical evaluation or care and hence, would not increase costs [65].  
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Therefore, we did not consider side-effects of antiviral medication in treated patients, whether 
they have influenza or not. 
 
This model assumed that all patients diagnosed with influenza, by either provider diagnosis or rapid 
test, were treated with antivirals.  If patients received antiviral therapy, we assumed that therapy was 
initiated within 48 hours of symptom onset and continued at the dose and length of treatment 
recommended by the pharmaceutical manufacturer. 
 
Influenza-related Complications 
For all patients, it was also assumed that the proportion of patients admitted to the hospital from the 
ED is similar regardless of influenza diagnosis or treatment.  For respiratory infections, ED 
clinician’s decision-making regarding patient disposition is likely based on the patient’s past medical 
history, appearance, physical examination, and laboratory and radiography results.  We assumed that 
a rapid diagnostic confirmation of influenza would not impact the likelihood to admit a patient to the 
hospital, nor would administration of antivirals have sufficient time to act and affect the decision to 
admit to the hospital.  As shown in Table 9, the proportion of influenza patients admitted to the 
hospital from the ED is estimated at 0.13 according to a retrospective evaluation of high risk patients 
presenting to the ED with influenza [31].  Alternate retrospective evaluations suggest the rate of 
admission in high risk patients could be as high as 0.57, which has been included as the peak range in 
the sensitivity analysis [66]. Subsequent complications after the decision of patient disposition from 
the ED are influenced by antiviral treatment and we thus evaluated for patients who have influenza 
but are not treated with antivirals compared to those with influenza who are treated with antivirals, as 
displayed in Table 9.   
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Hospitalized influenza patients can either die in the hospital or survive to discharge.  Hospitalized 
influenza patients who are treated with an antiviral have a lower risk of death (4%) compared to 
those who are not treated with an antiviral (10%) [11].  The mortality benefit of antivirals was 
explored in the sensitivity analysis ranging from no benefit (0% difference in mortality between 
treated and not treated), to 12% difference in mortality between treated and non-treated individuals.  
After discharge from inpatient hospitalization, we assumed that the patient incurred no additional 
complications or expenses, and that influenza resolved without further effects.   
 
Patients initially discharged from the ED either continued with no complications, had complications 
that required a repeat provider visit, or were subsequently hospitalized for influenza.  Previous 
studies have shown that antivirals reduce the rates of complications [67,68].  It was thus assumed that 
patients with subsequent complications had a repeat provider visit to address the complication, and 
that no patients died at home.  Several influenza complications require antibiotics, such as 
pneumonia, sinusitis, and otitis media, which have also been included in the analysis.  Proportions of 
all complications and those requiring antibiotics are listed in Table 9 for treated and untreated 
influenza patients. 
 
Quality Adjusted Life Years (QALYs) 
Several studies have demonstrated that antiviral medications reduce the duration of symptoms by 1.5 
– 2.5 days in both healthy and at-risk individuals [68].  One retrospective evaluation of the quality of 
life during a typical influenza illness using the EuroQol instrument found that influenza resulted in a 
0.883 reduction in health-state compared to baseline, which was used to calculate the QALY’s 
gained from reducing days of symptoms [69].  The QALYs gained from preventing a death depends 
upon the life expectancy.  The adult population at high risk of influenza complications consists of a 
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wide array of risk variables including being over the age of 65 and having chronic or acute medical 
illness.  It was assumed for the purposes of this analysis that the life expectancy of these patients is 
15 years, an estimate based upon the age distribution of patients considered to be at high risk for 
influenza complications in previous studies [70].  However, a range of life expectancy from 10 years 
to 30 years is included in the sensitivity analysis to evaluate the effect of a range of potential values 
for this assumption.  Using 3% discounting, 12.3 discounted QALYs are gained from preventing a 
death.  The estimated QALY’s used for this analysis are listed in Table 9. 
 
Diagnostics 
The clinical diagnosis of influenza is challenging to make despite numerous attempts to define a 
clear syndrome associated with influenza.  The most commonly used set of symptoms are fever with 
cough or sore throat, which is only 64% sensitive [24].  In an undifferentiated population with an 
acute respiratory illness, provider decision making has a poor sensitivity (0.29) and specificity (0.92) 
[42].  During the initial two days of symptoms, when antivirals are most effective, provider 
sensitivity raises to 0.67.  Thus, 0.67 was used as our base case sensitivity for provider decision 
making, but a range down to 0.29 was included in our sensitivity analysis.  The new molecular-based 
rapid diagnostic tests have a far superior sensitivity (0.91) and specificity (1.00) [27]. 
 
Costs 
Costs are estimated from a societal perspective and are in 2011 US dollars.  Costs not initially found 
in 2011 US dollars were converted to 2011 US dollars using the Medical Care Consumer Price Index 
[71].  All costs occur within the first year of diagnosis and treatment as influenza is an acute disease, 
therefore no discounting was performed on costs.  The cost of the initial ED visit was not included, 
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as this occurs before any specific treatment and testing, however the cost of testing and antiviral 
treatment was included for each patient receiving either.   
 
It was assumed that patients treated with antivirals will receive a full treatment course with 
oseltamivir, which is estimated to cost $100.60 [72].  Oseltamivir is the most commonly used 
antiviral, however Zanamivir is slightly cheaper, and can also be used.  Thus, these two prices 
included the sensitivity range for antiviral cost.  We did not include costs for the amantadines as 
they are currently no longer recommended for influenza treatment due to high rates of resistance.  
Some patients require antibiotics and amoxicillin was selected as the representative antibiotic.  
The majority of subsequent infections include sinus infections, ear infections, and pneumonias, 
all of which can be treated with amoxicillin.  Pneumonias in particular are often treated with more 
expensive antibiotics such as azithromycin or moxifloxacin for their added atypical bacterial 
coverage, and patients admitted to the hospital would likely require additional antibiotics to 
amoxicillin.  These more expensive antibiotics were considered in the sensitivity analysis.  
Details on medication costs are listed in Table 9. 
 
The expense associated with the rapid diagnostic test was estimated based on one of the new 
rapid influenza tests: Cepheid’s Xpert Flu assay.  The test is performed on a platform that is used 
for several other purposes in the hospital, and hence does not require specific purchasing for this 
purpose.  This cost-utility analysis assumes an ED setting in a moderately-sized hospital which 
would therefore carry this platform.  The overall price for the test includes 50$ for the test 





In the event of complications, the patient is likely to visit a medical professional either by 
returning to the ED, or seeing a primary care physician.  If the patient was initially evaluated in 
the ED, they are likely to return to the ED for follow- up care for the same reasons they originally 
sought care in the ED; either they have no primary care physician, are unable to make an 
appointment to see their primary care physician, or feel that their illness requires the higher level 
of care available in the ED.  Therefore, for the base case, the repeat visit was assumed to be in the 
ED.  A cost of a repeat ED visit is estimated at $304 per a previously performed cost analysis 
study evaluating the cost of treating influenza patients in the ED which estimated the true cost of 
medical care including medications, supplies, and health professional fees.  From this analyses we 
extracted the costs for patients over the age of 65 as a representative of our high risk patient 
population [66].  The cost of a primary care physicians visit, is substantially less, $72.11, as 
estimated by the American Medical association.  To account for potential variability, we used 
these two figures in the sensitivity analysis. 
 
Estimates of hospitalization costs were determined based on a previous cost analysis of the 
impact of seasonal influenza.  This cost analysis used a probabilistic model to estimate costs [70].  
To estimate hospitalization costs from this cost analysis, we used a weighted average of all 
medical care costs for all high risk adults who were hospitalized with influenza.  This average 
was weighted by the number of cases in each age group who were hospitalized.  
 
The population in question includes the elderly and those with chronic illnesses, so employment 
rates are likely to be lower than the general population.  To that end, it is assumed that 50% of 
this population is employed and works 8 hours a day at the national mean hourly wage of $22.02 
[73].  The actual proportion of employment and wage vary by location, so analysis was 
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performed with and without estimates of this indirect cost by allowing the sensitivity analysis 
range for this variable to decrease to 0.  Days of missed work were estimated to be 10 days in 
patients without influenza treatment and 7 days in those who receive antivirals based on the time 
to return to normal activities previous studies [67].  
 
RESULTS 
Base Case Analysis 
In the base case analysis, Treating None was clearly dominated by the other alternatives as it had the 
greatest cost ($1,260 95% CI 537-$4915) and least effectiveness (0 QALY saved by definition).  
Since there are other cheaper and more effective options, dominated alternatives, such as treating no 
patients, are not considered further as potentially cost-effective treatment options.  Treatment based 
on provider judgment had the lowest cost ($1,153 95% CI $528-$4727) but also a low effectiveness 
(0.014 QALY saved 95% CI 0.009-0.209).  This was followed by the treatment based on a 
molecular-based rapid diagnostic test with a slightly higher cost and effectiveness, and treating all 
patients, which had the highest cost, but also the highest effectiveness.  As shown in Table 10, the 
results for each of these options are expressed as a cost-utility ratio, which demonstrates the cost to 
gain one QALY in that particular testing and treatment arm.  Additionally, non-dominated 
alternatives are evaluated by the incremental cost-effectiveness ratio (ICER), which allows for 
comparison between two treatment arms, one of which has greater cost, but also greater 
effectiveness.  The ICER demonstrates the additional cost for each additional QALY saved by 
moving from the lower cost to the higher cost option.  The ICER between treatment based on 
provider judgment and treatment based on molecular-based rapid diagnostic testing was 
$1389/QALY saved, and the ICER between treatment based on molecular-based rapid diagnostic 
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testing and treating all, was $6249/QALY saved.  Both of these ICERs are below the $50,000/QALY 
willingness-to-pay threshold generally accepted in the US.   
 
Sensitivity Analysis 
A one way sensitivity analysis of influenza prevalence demonstrated the significant impact of 
prevalence on cost-utility.  At any potential prevalence greater than 0%, treating none was dominated 
by the other alternatives.  At a prevalence above 23%, rapid diagnostic testing dominated provider 
judgment.  At a prevalence above 26%, treating all dominated both provider judgment and rapid 
diagnostic testing.  Thus, between 1% and 23% prevalence, provider judgment, rapid diagnostic 
testing, and treating all (in order of increasing cost) were potential options.  Below a prevalence of 
approximately 3%, the ICER between provider judgment and molecular-based rapid diagnostic 
testing was greater than the $50,000/QALY threshold.  Between 3% and 7% prevalence, the ICER 
between rapid diagnostic testing and treating all was greater than the $50,000/QALY threshold.  
Between 7% and 23% prevalence, the ICERs between provider judgment and molecular-based rapid 
diagnostic testing, and molecular-based rapid diagnostic testing and treating all, remained below the 
$50,000/QALY threshold.  Adhering to the $50,000/QALY threshold, the most cost effective options 
are to treat based upon provider diagnosis from 0%-3% prevalence, treat based upon the results of 
molecular-based rapid testing from 3%-7% prevalence, and treat all above 7% prevalence.  Figure 3 
demonstrates the change in the ICER between treatment based on provider judgment and molecular-
based rapid diagnostic testing and the ICER between treatment based on molecular-based rapid 
diagnostic testing and treat all, both compared to the willingness-to-pay threshold over the range of 




Several one-way sensitivity analyses were performed to evaluate the impact of particular variables 
and assumptions on the ICER between treatment based on molecular-based rapid diagnostic testing 
and treating all.  As seen in Figure 4, a tornado diagram was performed to evaluate sensitivity 
analysis of the remaining variables indicated in the methods section.  A tornado diagram displays the 
results in order of potential impact on outcome with the variables with the greatest potential impact 
on the top and least impact on the bottom.  The greatest effect came from the cost of antiviral 
treatment, where a cost of less than approximately $78 lead to the treat all option dominating over the 
treat based on a molecular-based rapid diagnostic test.  Also with a significant impact on the 
outcome, if antiviral medications cause no improvement in mortality in admitted patients, then the 
ICER between rapid treatment and treating all is greater than the $50,000/QALY threshold indicating 
a potential benefit to treatment based on molecular-based rapid influenza testing.  However, a 
mortality benefit of even 0.5% in admitted patients taking antiviral medications reduces the ICER to 
below the $50,000/QALY threshold.  Notably, the remaining variables, probability of 
hospitalization, life expectancy, lost work costs, follow up visit costs, and cost of antibiotics did not 
have substantial impact on the most cost effective option. 
 
The cost-effectiveness acceptability curve shown in Figure 5 summarizes the repeated Monte Carlo 
simulations.  If a QALY had no economic value (willingness to pay equals zero), treatment based on 
provider judgment is the most economically preferred (saves the most money) in approximately 40 
percent of repeated simulations, followed closely by treat all which is the most economically 
preferred in 38 percent of repeated simulations.  This is followed by treatment based on molecular-
based rapid diagnostic treating which is most efficient in 20 percent of the simulations. As the 
willingness-to-pay for QALYs increases to the commonly used $50,000/QALY, treating all is most 
economically preferred in almost all the simulations, while the remaining options are rarely most 
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True to any cost-effectiveness analysis, the results are limited by the assumptions used to create 
the model.  This model only applies to patients are treated within 48 hours, as that is the 
commonly used time cut-off in much of the surrounding literature.  This time limit thus decreases 
the generalizability of this analysis in patients who present or are potentially treated later in their 
disease course.  Additionally, this analysis assumes that hospital admission and ED resource use 
is based upon the patient’s clinical presentation and would not be impacted positively or 
negatively by a diagnosis of influenza, whether by clinical judgment or rapid test.  Finally, this 
study utilizes a willingness to pay threshold of $50,000/QALY.  The exact monetary value of a 
QALY is subjective, and while we use this standard threshold to aid in interpretation of the data, 
consideration of the actual monetary value of one QALY spent should be considered. 
 
This analysis evaluates all adults at high risk of influenza-related complications, which is a varied 
group including those at risk due to age (age > 65), chronic illnesses, pregnancy, obesity, and 
those presenting with complications.  It is likely that the cost-effectiveness of the 4 testing and 
treatment regimens examined here vary within the above-referenced risk groups based on age, 
past medical history and severity of illness.  However, given the lack of literature describing 





This study additionally assumes that any patient diagnosed with influenza – whether by rapid test 
or clinical evaluation – receives antiviral treatment as we only included patients who are 
recommended to receive treatment according to CDC guidelines.  In reality this is not the case, as 
only 50% of high risk patients diagnosed with influenza in the ED receive antivirals [31].  
Previous studies have shown that use of a rapid influenza test increases antiviral prescription rate, 
likely due to increased physician confidence in the diagnosis of influenza [74].  Hence the 
simplified assumption that all diagnosed patients will be treated, likely places rapid diagnostic 
testing at a disadvantage compared to how each of the testing and treatment arms would likely be 
implemented in a real clinical setting.  Additional work is thus needed to evaluate the actual 
clinical utility of rapid testing and of provider diagnosis and the corresponding rates of antiviral 
prescription in high risk populations.  
 
Finally, this model provides a cost-utility analysis to provide information on a population level; 
however, there are additional factors which may affect ultimate decision making.  For example, 
this model does not attempt to model antiviral resistance patterns over time.  Some of the 
considered treatment algorithms, such as treat all, would likely lead to increased selection for 
resistant variants, which may, along with other unmeasured factors, affect ultimate clinical 
decision making.  
 
DISCUSSION 
This incremental cost-utility analysis is the first ever evaluation of influenza testing and treatment 
in patients with a high risk of influenza complications presenting to the ED with an acute 
respiratory illness in the era of new highly sensitive rapid diagnostics.  As demonstrated in 
previous analysis, the optimal method of influenza testing and treatment is highly dependent on 
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influenza prevalence, which changes rapidly throughout influenza season.  Assuming a 
$50,000/QALY willingness-to-pay threshold, the most cost effective treatment option is treatment 
based on provider judgment from 0-3% prevalence, treatment based on a molecular-based rapid 
influenza test from 3-7% prevalence, and treating all at greater than 7% prevalence.  These 
prevalences are based on a population presenting with a broadly defined respiratory illness, 
whereas previous studies have based their prevalence estimates on patients presenting with ILI, 
which is defined as fever and cough or sore throat [38].  While using the stricter criteria of ILI 
increases the prevalence of influenza in the testing population, it is also relatively insensitive, as it 
results in up to a third of influenza patients left untreated.  Hence, the prevalence levels 
referenced in this analysis are likely to be lower than the corresponding influenza prevalence 
amongst a more select group of patients with ILI. 
 
In considering the base case analysis, the three un-dominated treatment protocols, treat based on 
provider judgment, treat based on the results of a molecular-based rapid test, and treat all, do not 
differ substantial in terms of cost or effect, and are all superior to the treat none approach.  Thus 
in patients with high risk or current influenza complications, who present to the ED in less than 
48 hours, treatment with antivirals, whether based on provider judgment, rapid test, or treating all, 
results in decreased costs and increased benefit compared to not treating with antivirals.  Which 
of the three treatment options is most cost effective depends on prevalence, and other individual 
and societal factors.  In all but the lowest prevalences, treatment based on molecular-based rapid 
testing results in improved outcomes, compared to provider judgment, with a minimal additional 
cost of $1389/QALY in the base case scenario.  The treatment based on molecular-based rapid 
testing option has the added benefit of influenza testing, and hence information regarding 
influenza prevalence to inform future decision making.  From a strict cost-effectiveness 
perspective, the treat all option is similarly favorable at a prevalence above 7% with an ICER of 
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$6,246/QALY in the base case analysis.  However, the treat all option raises some concerns 
regarding subsequent development of antiviral resistance due to heavy antiviral use.  Although 
this analysis was taken from a societal perspective, we did not attempt to estimate how the rates 
of antiviral treatment would affect developing viral resistance for the two remaining effective 
antiviral medications, oseltamivir and zanamivir.  The optimal method of administering antiviral 
treatment to high risk influenza patients is likely influenced by additional considerations not 




Overall, the most cost effective method of influenza testing and treatment in high risk ED patients 
depends on local influenza prevalence; however, with any active influenza, antiviral treatment of 
any kind is superior to no treatment.  Given the rapidly changing prevalence, the costs and effects 
of each treatment algorithm varies throughout the influenza season, and the most efficient ED 
policy may change throughout the influenza season.  From a practical standpoint, providers in 
acute care settings would thus benefit from having real-time estimates of the prevalence of 
disease in their community or locale in order to make the most cost effective decisions for 
evaluating and treating patients who may have influenza.  Although promising methods are being 
developed for real-time influenza monitoring, additional research combining surveillance with 


























Figure 3: One-way Sensitivity Analysis of Influenza Prevalence: Incremental Cost 
Effectiveness Ratios (ICER) comparing treatment based on provider judgment to treatment 
based on a rapid PCR test (dotted line) and treatment based on provider judgment to treat all 
(dashed line), compared to the accepted willingness-to-pay threshold of $50,000/QALY (solid 
line). 
 





















































































































ICER of treatment based on provider judgment compared to treatment based on a
rapid PCR based test





Figure 4: Tornado Diagram displaying Incremental Cost-effectiveness Ratio (ICER) between 
treatment based on molecular-based rapid Influenza Testing and Treat All algorithms 
 





Figure 5: Cost-Effectiveness Acceptability Curve of Monte Carlo Simulation results across a 
range of Willingness-to-Pay Thresholds 
 





































Willingness-to-pay (2011 US $/QALY) 
Provider Judgment Rapid Diagnostic Test Treat All Treat None
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Sensitivity Range Source 
Influenza Variables:    
Probability of Influenza in ED patient with acute 
respiratory illness 
0.20 0.0 – 0.60 [42] 
Proportion of ED patients admitted 0.13 0.13 - 0.57 [31,66] 
Untreated Influenza:    
Probability of death in hospitalized patients 0.10 0.06 - 0.14 [11] 
Proportion with complication requiring repeat 
PCP/ED Visit 
0.46 0.30 - 0.62 [67,68] 
Proportion with complication requiring 
antibiotics 
0.38 0.23 - 0.53 [67,68] 
Proportion re-hospitalized after discharge 0.032 0.015 - 0.049 [75] 
Length of influenza illness, days 7.5 3.5 - 14.5 [67,68] 
Missed work, days 10.0 5.5 - 20.5 [67] 
Treated Influenza:    
Probability of death in hospitalized patients 0.039 0.002 - 0.078 [11] 
Proportion with complication requiring repeat 
PCP/ED Visit 
0.14 0.03 - 0.25 [67,68] 
Proportion with complication requiring 
antibiotics 
0.14 0.03 - 0.25 [67,68] 
Proportion re-hospitalized after discharge 0.016 0.003 - 0.029 [75] 
Length of influenza illness, days 5.0 3.0 - 9.0 [67,68] 
Missed work, days 7.0 4.0 - 16.0 [67] 
QALYs Gained by antiviral treatment:    
QALY gained for improvement of symptoms 
with antiviral use 
0.006   
QALY gained per hospitalized patient due to 
decreased mortality 
0.75 0.61 - 1.83  
Rapid influenza test characteristics:    
Sensitivity 0.91 0.85 - 0.95 [53] 
Specificity 0.99 0.97 - 1.00 [53] 
Provider Decision Making:    
Sensitivity 0.67 0.29 – 0.67 [42] 
Specificity 0.92 0.92-0.96 [42] 
Costs (In 2011 US dollars):    
Antiviral (full treatment course) $100.60 $72.95 - $100.60 [72] 
Antibiotic (full treatment course $3.69 $3.69 - $68.91 [72] 
Rapid diagnostic test $53  Cepheid 
Repeat Visit – ED or Primary Care physician $303.87 $72.77 - $303.87 [66,76] 
Hospitalization (with survival) $31,970 $31,541 - $32,399 [70] 
Hospitalization (with mortality) $52,646 $50,572 - $54,717 [70] 
Mean hourly Wage $22.02  [73] 





Table 10: Base Case Cost-utility Ratios with 95% Confidence Intervals of estimates based on 

































0.000 >100,000 Dominated 
QALY: Quality Adjusted Life Years 






Each year influenza affects 5-20% of the population, many of whom present to the ED for initial 
evaluation and treatment.  Diagnosing influenza in the ED remains a challenge as physicians have 
no reliable tools to accurately and rapidly diagnose influenza; however, rapid diagnosis is crucial 
to begin antiviral therapy in patients with complications or at risk of complications from influenza 
as treatment is most effective when given within 48 hours of symptom onset.  CDC Guidelines 
recommend antiviral treatment for patients who are hospitalized, at extremes of age (<5 years old, 
>65 years old), or have a chronic disease or conditions putting them at increased risk of 
complications.  Given the lack of validated, sensitive, rapid testing, and the benefits of early 
treatment, the CDC currently recommends that providers initiate treatment in high-risk 
populations based on physician judgment and clinical signs and symptoms without waiting the 
extended period of time to confirm the diagnosis.  However, clinical symptoms such as cough and 
fever have a sensitivity of only 64% and have been shown to be insufficient to diagnose or rule 
out influenza through numerous meta-analyses.  As a result of the current diagnostic difficulties, 
providers often do not suspect, or are not confident in a diagnosis of influenza, resulting in 
misdiagnosis and under-treatment.  Sensitive rapid testing is essential to improve diagnostic 
accuracy, allow for targeted antiviral therapy, and facilitate rapid antiviral administration which 
has been linked to improved patient outcomes in high risk populations. 
 
New molecular-based rapid tests, such as Cepheid Xpert Flu, show greatly improved sensitivity 
compared to previous antigen-based rapid tests; however, they have yet to be validated in a 
generalized population.  Integration of this rapid test into the ED environment is further 
complicated by the expense of molecular-based testing in a resource-limited environment, and 
lack of an easily identifiable testing population as classic ILI symptoms such as fever and cough 
have poor sensitivity.  This study evaluated both current antiviral administration rates and clinical 
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influenza diagnostic accuracy in the ED.  In addition, it characterized the clinical performance of 
Xpert Flu and evaluated the cost effectiveness of implementing molecular-based rapid testing in 
an applicable clinical setting. 
 
There are several factors which may impact a clinician’s decision to treat with antivirals including 
difficulty in diagnosing influenza, concern of the effectiveness of antivirals, antiviral cost, and 
increasing antiviral resistance.  This work confirms that there is poor adherence with CDC 
recommendations for influenza antiviral treatment amongst ED patients.  A retrospective cohort 
of patients with laboratory confirmed influenza from a clinically obtained influenza test sent from 
the ED demonstrated that only 41% of patients meeting CDC criteria for recommended treatment 
actually received antivirals.  The most compelling evidence of the impact of antiviral treatment is 
in patients with severe disease, such as patients requiring hospital admission, where antivirals 
have been shown to reduce mortality.  Thus, if concerns of antiviral effectiveness were the 
primary driver for clinician decision making, one would expect clinicians to prioritize treatment 
in this population with severe disease and greatest potential benefit.  However, there was no 
association between antiviral treatment and markers of severity of illness such as hospital 
admission or the pneumonia severity index.  This suggests that concern of antiviral effectiveness 
is not a primary factor in clinician decision making regarding antiviral treatment. 
 
The retrospective cohort showing that 41% of patients recommended for antiviral treatment by 
the CDC actually received treatment was in a population where the patient received clinical 
influenza testing.  Thus, in this population, a clinician considered influenza in the diagnosis as 
evidenced by the order of a clinical test.  A subsequent prospective cohort, which systematically 
tested all patients with an acute respiratory illness who met CDC criteria for antiviral treatment, 
demonstrated a lower rate of compliance with CDC guidelines.  In this broad population, which 
was unbiased by the clinician’s clinical concern for influenza, only 26% of patients with 
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laboratory confirmed influenza received antiviral treatment from the ED.  This difference 
demonstrates how physician diagnosis, or consideration of an influenza diagnosis, impacts 
treatment.  Other factors indicating that the clinician was confident in a diagnosis of influenza, 
such as a diagnosis of influenza recorded in the electronic medical record, and a positive 
influenza test which resulted during the patient’s ED visit were associated with antiviral 
treatment.  Taken together, these factors suggest that difficulty in diagnosing influenza has a 
considerable impact on antiviral treatment. 
 
Unfortunately, diagnosing influenza in the ED is a challenge as no sensitive tests are rapidly 
available and clinical signs and symptoms have poor sensitivity for influenza.  To identify the 
sensitivity and specificity of clinician diagnosis, we systematically tested ED patients with an 
acute respiratory illness during influenza season, and obtained the clinician’s diagnosis by asking 
the clinician: “Do you think this patient has influenza?”.  This study was restricted to an ED 
population of subjects who meet CDC criteria for recommended antiviral treatment as that is the 
population in which an accurate diagnosis of influenza is most critical as it would potentially 
impact clinical decision making regarding antiviral treatment.  In this evaluation, we found that 
clinician diagnosis had a very low sensitivity of 36% and specificity of 78%.   
 
Provider diagnosis is partially based on the patients presenting signs and symptoms.  Numerous 
studies have demonstrated that signs and symptoms are not sensitive for influenza [24-26].  
However, the majority of these studies are biased by the fact that fever is a mandatory inclusion 
criteria.  Not surprisingly, these studies have found that fever is the most significant indicator of 
influenza [24-26].  In our prospective evaluation, patients were included if they had at least one 
symptom of an acute respiratory infection which included cough, sinus pain, nasal congestion, 
rhinorrhea, sore throat, shortness of breath, or fever.  These broader inclusion criteria allowed for 
a more accurate evaluation of signs and symptoms in high risk patients with influenza.  Among 
71 
 
patients with influenza, only 31% had the classic symptoms of ILI, according to the CDC 
definition of fever with couth or sore throat.  This value is substantially lower than previous 
estimates, and was lower in patients with existing or at increased risk of complications compared 
to non-high risk individuals.  This clearly demonstrates that classic symptoms such as ILI are not 
reliable to diagnose influenza in a high-risk population. 
 
A new generation of molecular-based rapid influenza tests are currently available, but are not yet 
integrated into clinical practice.  One of these tests, Cepheid Xpert Flu, yields results in 80 
minutes, and has demonstrated high sensitivity in retrospective samples.  To evaluate potential 
integration into clinical care, we evaluated the performance of this test in a target clinical 
population of high-risk ED patients with undifferentiated respiratory illness.  In this population, 
the same used to evaluate the performance of clinician diagnosis, Xpert Flu had a sensitivity of 
95% and specificity of 99%, vastly outperforming clinical diagnosis.  This demonstrates that 
Xpert Flu is a viable solution to the challenges of influenza diagnosis in the acute care setting.  
Access to a reliable and timely diagnostic test, such as Xpert Flu, could improve compliance with 
CDC antiviral treatment guidelines.  As with integrating any new test or technology, cost remains 
a concern. 
 
In order to address cost concerns for both the expense of antivirals, and that of potentially 
integrating new rapid influenza testing, we performed a cost utility analysis comparing four 
influenza testing and treatment strategies: 1) Treat none, 2) Treat based on provider judgment, 3) 
Treat based on results of a molecular-based rapid diagnostic test, and 4) Treat all.  Given 
concerns of the lack of sensitivity of clinical signs and symptoms as previously demonstrated, this 
analysis was performed using a societal perspective, and a broad population of ED patients 
recommended to receive antiviral treatment according to CDC guidelines with an acute 
undifferentiated respiratory illness.  This analysis demonstrated that the most cost effective 
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method of managing influenza was directly related to prevalence of influenza.  At a prevalence of 
less than seven percent, using a molecular-based rapid diagnostic test, such as Xpert Flu, was 
most cost effective.  When the prevalence rose above seven percent, treating all was the most cost 
effective management option.  The current method of treating according to clinical judgment was 
only cost effective at the absolute lowest prevalence.   
 
This cost utility analysis did not take into account additional factors such as antiviral resistance, 
which is a continuing concern an often cited reason for not administering antivirals.  Our 
prospective evaluation demonstrated significant antiviral overtreatment, with 11% of patients 
who were negative for influenza receiving antivirals.  Though this concern may prevent clinicians 
from treating undifferentiated patients with an acute respiratory illness, integration of rapid 
influenza testing would allow for targeted antiviral testing and subsequently reduce this 
overtreatment in influenza negative patients.   
 
Currently, there is poor compliance with current CDC guidelines for antiviral treatment amongst 
ED patients presenting with an acute respiratory illness.  Part of this poor compliance is due to the 
challenges of influenza diagnosis in the ED.  Clinical diagnosis, which is commonly used in 
many EDs, has very low sensitivity for influenza, likely contributing to the overall poor 
compliance with antiviral treatment guidelines.  Improving diagnosis by integrating a molecular-
based rapid influenza test into clinical care could result in improved compliance with current 
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